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ABSTRACT
Human immunodeficiency virus (HIV) is a chronic illness affecting more than 32.7 million
individuals worldwide. The virus infects immune cells, weakening the immune system overtime
eventually leading to acquired immunodeficiency syndrome (AIDS) if left untreated. Infection
starts with a fusion step, followed by uncoating of the HIV capsid once in the cytoplasm of the
cell. HIV uses host cell proteins to complete the infection process, like the actin associated
factor, SPTBN1. The Hulme lab has previously shown that SPTBN1 knockdown by siRNA in
microglial cells decreased HIV infection and delayed uncoating of HIV. Because fusion is prior
to uncoating, it is important to verify that fusion delay was not the reason uncoating was delayed.
The goal of this thesis research was to further determine the role of SPTBN1 in HIV infection of
microglial cells that are a natural host for HIV. The siRNA knockdown of SPTBN1 was
optimized, achieving knockdown between 67-94%. A knockdown of SPTBN1 was done to
confirm that it decreases infection, and the fusion kinetics were observed by a fusion assay. The
fusion step of HIV infection was determined to not be affected by SPTBN1 knockdown with
fusion kinetics being similar to control conditions. These results support the labs previous
conclusion that SPTBN1 is involved in the uncoating step of HIV infection that follows fusion.
Researching hosts factors such as SPTBN1 provide important insights to how HIV infects cells
and identifies areas of interest that can be targeted by medications.
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INTRODUCTION

Human immunodeficiency virus (HIV) is the virus that causes acquired
immunodeficiency syndrome (AIDS). From 1981 to 2019, 32.7 million people died from AIDSrelated illnesses (1, 2). There are two types of HIV, HIV-1 and HIV-2. HIV-2 is less common in
human infection, less pathogenic, and has a slower disease progression than HIV-1 (3). HIV is a
virus that originated in monkeys as the simian immunodeficiency virus (SIV) that mutated to
infect humans making it a zoonotic virus. The virus became infectious to humans in four cross
species infection events where individuals came in contact with infected fluids. Each of these
events led to a new group of HIV-1 virus (1, 4). The most common group of HIV-1 came from
chimpanzees in Africa (1).
The four groups of the HIV-1 virus are M, N, O, and P. Determined based on the genetics
of the viruses, the M and N groups were transferred to humans from the SIV of chimpanzees (4).
The O and P groups are from SIV in gorillas (4). The M group of HIV-1 virus is the most
common, accounting for 99% of the world’s infections. Within the M group there are subtypes
A, B, C, D, F, G, H, J, and K (4). The subtypes are created by the high mutation rate of HIV-1
due to the viral reverse transcriptase. The reverse transcriptase enzyme of HIV-1 has no
proofreading activity, leading to a mutation rate of about 10-5 mutations per basepair for each
replication cycle (4, 5). This mutation rate in the HIV RNA genome is much higher than
mutation rates of 10-7 mutations per basepair within DNA viruses that do not use reverse
transcriptase in the infection process (5, 6). There are also forms of the HIV-1 virus that are
combinations of subtypes, called circulating recombinant forms (7). The high mutation rate
makes it difficult to effectively target HIV-1 for treatment.
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HIV is spread through infected blood, seminal fluids, breast milk, rectal fluids, and
vaginal fluids (1). To establish infection, HIV-1 targets immune cells with CD4 receptors present
on their membrane (8, 9). These cells help fight bacteria and viruses that enter the body, so it is
important to have many healthy CD4+ cells. A normal CD4 cell count is between 500 to 1500
cells per millimeter3 of blood. The HIV-1 genome integrates into the CD4+ host cell genome and
activates the DNA damage response. The activation of DNA-dependent protein kinase causes a
signal cascade that causes the death of the CD4+ cells after the HIV-1 infection process (10).
HIV-1 infection causes the decreased CD4 count of patients as the disease progresses. This
prevents the immune system from being able to properly fight off infections within the body
(11).
HIV-1 infection proceeds through three clinical phases. The first stage is acute HIV-1
infection, where the individual is highly contagious due to large amounts of HIV-1 in their blood
and is characterized by mild flu-like symptoms (1, 2). This first stage happens a couple weeks to
a month after HIV-1 infection and can last a few days to weeks with a wide range of symptoms.
The second stage of HIV-1 progression is the clinical latency or chronic HIV-1 infection. The
viral load is very low in the body and individuals usually have few if any symptoms of infection.
This stage, without treatment, can last 10 to 15 years for regularly progressing individuals with a
gradual decrease of CD4+ cells as time goes on (1, 2). During this stage, HIV-1 has inserted its
genome into host cells but is not being replicated, creating the viral reservoir and latent infection
(1). The last stage of HIV-1 infection is the progression to AIDS. AIDS is due to the body’s
immune system being weakened by the virus, allowing for opportunistic infections to occur.
Individuals are diagnosed with AIDS when their CD4 count is less than 200 cells per millimeter3
of blood, down from the 500 to 1500 normal cell count, or an individual develops opportunistic
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infections (1, 2). During the last stage of HIV-1 progression, individuals have high viral loads
and are very infectious (1, 2). The life expectancy of someone with AIDS without treatment is
approximately a year, where death is a result of infections from the weakened immune system.
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LITERATURE REVIEW

HIV-1 and the Immune System
Target cells of HIV-1 includes dendritic cells, CD4+ T cells, and macrophages (8, 12).
These cells are all part of the human body’s immune system responsible for recognizing foreign
harmful molecules in the body and fighting them off. It is a complex network of cells signaling
one another to initiate a response to a potential harm (13). The immune system has two parts: the
innate immune system and the adaptive immune system. The generalized immune response is the
innate immune system that works quickly when a foreign molecule first tries to enter the body.
The innate immune system relies heavily on membranes of the body to physically prevent germs
from entering. If the foreign molecule enters the body, many immune cells go toward the site of
entry to destroy the molecule. The cells involved in this response includes granulocytes, mast
cells, macrophages, and dendritic cells (14–16).
The adaptive immune system is a specialized response to foreign molecules in the body.
The adaptive immune response activates if the innate immune response fails to fight off the
foreign molecule that entered the body. This is a slower response because the cells must
specifically identify the pathogen to fight it. Though this is a slower response, it is more long
term because the cells recall a pathogen if it has fought it off once. If the foreign molecule enters
the body again, the adaptive immune system will quickly and effectively fight off the infection.
The cells involved in the adaptive immune system include B cells and T cells (15, 16) . These
cells will increase the immune response by signaling and recruiting other immune cells to the
area of infection.
The HIV target cells are important for the immune system to work properly.
Macrophages are derived from monocytes as part of the innate immune response. Macrophages
4

engulf bacteria to destroy them. Dendritic cells are antigen-presenting cells involved in the innate
immune system that can also be derived from monocytes. Dendritic cells receive the antigens
from their environment and recognize pathogens. The antigen presented on the cell is recognized
by adaptive immune cells to specifically target pathogens. B cells and T cells as part of the
adaptive immune system will bind to the antigen presented on the dendritic cell and use it to
ramp up the immune response (16). T cells will recruit other immune cells to better fight and
destroy the pathogen. The immune system and all cells involved are required to keep us healthy.
HIV infection disrupts the ability of the immune system to properly fight off infection because it
infects the immune cells themselves.
Different immune cells are specialized and localized to various areas of the body to be
the most effective at fighting off illness at those areas. Microglial cells are specialized
macrophages present in the Central Nervous System (CNS) at high quantities and a natural host
for HIV-1 (17). Microglial cells are primarily responsible for the innate immune system within
the CNS. These immune cells are slow growing and can survive for over four years. Microglial
cells are the long-lasting cells when infected with HIV-1 and cause incessant infection that
prevents eradication (17). These cells contribute to the viral reservoir with HIV-1 permanently
integrated into their genome, leading to the progression of the disease (17). The viral reservoir is
the biggest barrier for curing HIV infection.
Microglial cells are the largest part of the HIV viral reservoir in the brain. The viral DNA
lays dormant in the cell and with every division cycle the new cells contain the HIV genome as
well. The microglial cells can then be activated through various extracellular factors including
different cytokines and chemokines. Increase of the viral loads further progresses patient illness
during the end of the chronic HIV infection stage (18). It is biologically relevant to study these
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natural host cells that make up the HIV reservoir. The microglial cells are especially important
when talking about HIV-1 associated neurocognitive diseases (HAND). When HIV-1 infects
microglial cells, it can cause them to release neurotoxic factors and cause neuron degeneration.
These natural host cells are important to study and understand for treating HIV-1 and HANDs it
can cause.

Treatments for HIV-1 Infection
There is currently no cure for HIV-1 infection, but since the epidemic began there has
been great progress in treatments for infected individuals as well as preventative treatments for
high-risk groups. Individuals more likely to encounter HIV-1 contaminated fluids are within
these high-risk groups. High-risk individuals can work to prevent HIV-1 infection by avoiding
using nonsterile syringes, using protection during sex, and taking preventative prescription
therapies. For individuals at increased risk of HIV-1 infection there is pre-exposure prophylaxis
(PrEP) medication available (1). Anyone that has recently been exposed to HIV-1 may take postexposure prophylaxis (PEP) medications to prevent infection. After someone has been infected
and is HIV-1 positive, there are also medications to prevent the progression of the disease. These
medications, called antiretroviral therapies (ART), work to reduce the HIV-1 viral load in the
body, slowing the progression of the disease and helping to prevent new infections (1). For these
therapies to be effective, they must be taken consistently as prescribed to keep the viral load low.
Antiretroviral therapy is a lifelong treatment to prevent HIV-1 infection progression.
Individuals should start ART as soon as possible after HIV-1 infection to slow progression of
symptoms (1, 7, 19). The types of ARTs disrupt specific HIV-1 replication processes including
nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase
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inhibitors (NNRTI), integrase inhibitors (INSTI), protease inhibitors (PI), entry inhibitors, or a
combination thereof (7, 20).
Each of these have a slightly different mechanism to block HIV-1 infection. NRTIs are
structured similar to a nucleotide that would be added during the reverse transcription process
but does not have a 3’ hydroxyl for the next base of DNA to add on to. This drug treatment halts
reverse transcription, stopping the HIV-1 infection process (20). NNTRIs also work to stop
reverse transcriptase activity, but these bind to the enzyme creating a hydrophobic site near the
active site that prevents efficient reverse transcription. The reverse transcription activity is
greatly decreased and helps prevent further HIV-1 infection (20). INSTIs block the transfer of
the viral DNA into the host cell genome by binding to the integrase active site. Integration of the
viral DNA into the host cell genome is required for subsequent HIV-1 infection (20). PIs act in a
similar way to INSTIs by binding to the enzyme, in this case protease, and preventing it from
performing its function. The protease enzyme is involved in the maturation of HIV-1 virus by
cleaving the polyproteins into separate proteins. The cleavage of the proteins is needed for the
virus to mature and be able to infect further cells (20). The final treatment option is a multitude
of entry inhibitors. These work to prevent HIV-1 from enter any host cells, stopping the infection
process before it starts (20).
Treatment plans often include multiple types of medications used in combination. This
combination therapy works at multiple steps in the HIV-1 replication process to help prevent
progression of the disease (7). Due to the high mutation rate of HIV-1, resistance to the
medications occurs easily if the patient is not adhering to their treatment plan (7). The HIV-1
replication cycle and structure are researched widely to find more effective treatments for
patients.
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Structure of HIV-1
An HIV-1 virion is an enveloped virus particle that includes the RNA genome
surrounded by a protein capsid. The structure of HIV-1 contains two RNA copies of the viral
genome to encode the three polyproteins and various accessory proteins (21). The three
polyproteins are the group-specific antigen (Gag) protein, the polymerase (Pol) protein, and the
envelope glycoprotein (Env; ((21)). Each of the polyproteins is cleaved into multiple separate
proteins. The Gag protein is cleaved by a viral protease to form the matrix (MA), capsid (CA),
and nucleocapsid (NC) proteins. The Pol is cleaved by a viral protease to form the enzymes of
the virus; protease (PR), reverse transcriptase (RT), and integrase (IN; (21)). The Env
polyprotein is what makes up the envelope of the HIV-1 virus which includes the surface (SU)
Env glycoprotein, gp120, and the transmembrane (TM) glycoprotein, gp41 (21). The Env
polyprotein is cleaved by a host cell protease, unlike the viral protease that cleaves the Gag and
Pol proteins (21). The Pol, Env, and Gag proteins are essential in the replication process of HIV1.
A few regulatory and accessory proteins are encoded by the HIV-1 genome as well. The
trans-activator of transcription protein (Tat) plays a role in transcribing the HIV-1 genome (21).
The Tat protein activates the transcription of the viral long terminal repeat (LTR) promoter (22).
The 5’ LTR contains the promoter for the viral genes integrated into the host cell (22, 23).
Transport of the viral RNA from the nucleus to the cytoplasm requires the RNA splicingregulator (Rev) protein encoded within the HIV-1 genome (21). The Rev protein has a nuclear
localization signal and RNA binding sites to export viral RNA from the nucleus for translation to
occur in the cytoplasm (24).
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The accessory proteins present in the structure of HIV-1 are Nef, Vpr, Vpu, and Vif (21,
23). The negative factor (Nef) is involved in the downregulation of the CD4 receptor and major
histocompatibility complex I, as well as the activation of p21-activated protein kinase to improve
the ability of a virion to infect a cell (25). The viral protein R (Vpr) has many roles in increasing
infectivity of the HIV-1 virus, especially in macrophages. Vpr increases replication of the virus,
increases the effect on T cells, and is one of the most prevalent proteins within the HIV-1 virion
(26). The viral protein U (Vpu) is a viroporin that can modify membranes to help with trafficking
in the cell and release of HIV-1 from the host cell (23). Vpu is also involved in the
downregulation of CD4 receptors on the host cell (27). The viral infectivity factor (Vif) plays a
major role in ensuring infection of the virus. Vif binds to the immune factor APOBEC3G, that
usually targets and destroys retroviruses, to instead initiate the ubiquitination and degradation of
APOBEC3G, allowing for the survival of HIV-1 (28). APOBEC3G, encoded by HIV-1 host
cells, is a DNA editing enzyme that has antiviral properties making it a restriction factor (29).
Vif is an important viral factor for efficient HIV-1 infection, protecting against the antiviral
effects of APOBEC3G (29).
The structure of the HIV-1 virion is vital for the efficient infection of a host cell (Fig. 1).
The arrangement of the proteins within the mature virus starts on the membrane with the Env
proteins gp120 and gp41. The gp120 protein (pink in Fig. 1) is on the outside of the virus and
binds to the host cell membrane proteins. The gp41 protein is the transmembrane protein (green
in Fig. 1) that attaches the gp120 protein to the membrane of the virus (30). Both gp41 and
gp120 proteins are involved in the fusing of viral and host cell membranes (23). The matrix
protein localizes just under the membrane of the HIV-1 virus (light blue in Fig. 1). The capsid
proteins form a conical structure surrounding the viral genome (dark blue in Fig. 1). The HIV-1
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capsid is made of approximately 1,500 capsid monomers that form hexamers and a few
pentamers to make the conical structure (31). The viral RNA within the capsid has nucleocapsid
bound to it, protecting it and forming the RNA complex (black RNA with yellow NC in Fig. 1;
(23, 30, 32)). The reverse transcriptase (orange in Fig. 1) and integrase enzymes are held within
the capsid core enabling them to interact with the viral RNA (30). The reverse transcriptase
enzyme converts the viral RNA to DNA that is processed at the LTR regions by integrase that
also incorporates the viral DNA into the host cell DNA (23).

HIV-1 Replication Cycle
Binding of the virus to a host cell receptor is the start of the replication cycle for HIV-1
allowing for fusion of the host and viral membranes (Fig. 2 step 1; (9, 33)). The HIV-1 envelope
protein gp120 binds to the CD4 receptor on target cells (9). When the virus binds to the CD4
receptor on a host cell, a conformational change occurs allowing a bridging sheet domain to
form. The new domain becomes the binding site for the co-receptor, either CCR5 or CXCR4.
The CCR5 co-receptor is the most common and helps stabilize the membrane proteins once
bound to the CD4 receptor (9). The gp41 protein attached to the gp120 protein in the envelope of
HIV-1 has a conserved sequence called a fusion peptide that initiates fusion of the two
membranes (33). After receptor binding, the fusion peptide inserts itself into the host cell
membrane. The gp41 protein then forms a stable trimeric 6-helix bundle that brings together the
two membranes for fusion (33).
Once the viral membrane and host membrane fuse, the HIV-1 viral core is released into
the host cell cytoplasm where uncoating and reverse transcription initiate to turn the viral RNA
into DNA (Fig. 2 step 2 and 3; (31, 34, 35)). Reverse transcription is carried out by reverse
transcriptase starting at the 3’ C terminal end of the viral RNA converting it into double stranded
10

DNA and creating the reverse transcription complex (RTC; (35)). This complex contains viral
RNA, newly made DNA, and various associated viral proteins including CA (36). Reverse
transcription initiates in the cytoplasm and is completed once in the nucleus (31, 37). Research
has shown that some intact capsid must be associated with the RTC when the viral genome
enters the nucleus as it interacts with the nuclear pore (31, 34). The RTC forms into the preintegration complex (PIC) once the viral RNA is completely converted into DNA (Fig 2. Step 4;
(31, 37)). The reverse transcribed viral DNA contains long-terminal repeats on the ends that are
processed by integrase, preparing the viral DNA for integration into the host cell genome (38,
39). The integrase binds to the LTR and carries out endonuclease cleavage to remove two
nucleotides that allow for the strand transfer process to begin. The strand transfer integrates the
viral DNA into the host cell DNA (40). The order of HIV-1 infection steps uncoating, reverse
transcription, and nuclear import are not entirely known as each step may have different
mechanisms depending on the host cell. Uncoating is the process of the HIV-1 viral capsid core
subunits disassociating from the reverse transcription complex (RTC; (31)).
Given these data, there are three main models of HIV-1 uncoating and reverse
transcription including the cytoplasmic, nuclear pore complex (NPC), and nuclear uncoating
models (Fig. 3). A previous model that has been widely disproven is the immediate uncoating
model (41–43). This model proposed the HIV-1 capsid disassociated from the genome almost
immediately after fusion with the host cell (31). The three current models are representations of
ways reverse transcription and uncoating may occur during HIV-1 infection, with evidence
supporting all three (31, 42). The cytoplasmic uncoating model has the capsid slowly
disassociating as it moves toward the nucleus of the cell and reverse transcription happening at
the same time (Fig. 3 left). The NPC uncoating model describes the capsid remaining stable until
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it docks at the nuclear pore where the reverse transcribed viral DNA enters the nucleus (Fig. 3
middle; (31)). The newest model of capsid uncoating is the nuclear model. This model has the
entire HIV-1 capsid entering the nucleus of the cell before uncoating occurs (Fig. 3 right; (42)).
The process of uncoating is uncertain but likely to occur as one of these models or a combination
thereof depending on the host cell.
Research has shown various results about where reverse transcription and uncoating start
and finish. Reverse transcription most likely starts in the cytoplasm and finishes within the
nucleus (37). There are reverse transcription molecules shown within the nucleus. Uncoating of
the capsid may start in the cytoplasm or occur at docking and import into the nucleus (36, 37,
43). Capsid molecules have been shown to be associated with the HIV genome while in the
nucleus, but it is not known the extent or configuration of the capsid remaining intact when in the
nucleus (44). The mechanisms of uncoating may also depend on the cell that is being infected as
different host factors can affect the infection process.
The previous steps of replication, binding, fusion, reverse transcription, and uncoating,
are happening at the host cell membrane, in the cytoplasm, and finishing in the nucleus of the
cell (Fig. 2 and 3). The HIV-1 complex enters the nucleus through a nuclear pore complex
(NPC). NPCs are embedded in the membrane of the nucleus of the host cell and regulate
movement in and out of the nucleus. The NPC is made of nucleoporins (Nup) that interact with
molecules such as the HIV-1 genome. The viral DNA is trafficked to the NPC where
nucleoporins assist in the nuclear import process (Fig. 2 and 3; (45)). The proper translocation of
HIV-1 through the NPC is thought to specifically rely on Nup153 and Nup358. Nup358 forms a
basket on the cytoplasmic side of the NPC while Nup153 forms a similar structure on the
nucleoplasm side (46). Once the HIV-1 DNA is in the nucleus, the integrase on the ends of the
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DNA catalyzes the integration of the viral DNA into the host genome (Fig. 2 step 4; (47)). The
stages of HIV-1 replication up to integration are considered the early stages of infection.
After integration of the HIV-1 genome into the host cell genome, HIV-1 starts to
replicate within the host. The HIV-1 genome is transcribed within the host cell and using the
cells machinery. The HIV-1 RNAs are exported out of the nucleus and are translated to the
polyproteins: Gag, Pol, and Env (Fig. 2 step 5; (48)). These polyproteins localize to the surface
of the host cell membrane. With all HIV-1 proteins at the host cell membrane, the virus buds off
(Fig. 2 steps 5 and 6). After the HIV-1 virus buds from the host cell the virus cleaves the
polyproteins and organizes them creating the mature HIV-1 virus that can infect other cells (Fig.
2 step 7; (48)).

Cytoskeletal Function in HIV-1 Infection
The infection process of HIV-1 is assisted by cellular host factors. These factors
contribution to infection can be observed through knockdowns of the protein factors and
observing the effect on HIV-1 infection. Oppositely, HIV-1 restriction factors are within the host
cell and prevent effective infection, like the previously mentioned APOBEC3G. When
APOBEC3G is present, there is a lower HIV-1 infection efficiency (49). Inhibition of
cytoskeletal factors like Rho GTPase, cause a decrease in HIV-1 infection (50). Rho GTPases are
involved in actin organization specifically, but many factors associated with both actin and
microtubules are known to play a role in HIV-1 infection (50).
During infection the viral complex is trafficked through the cytoplasm towards the
nucleus with the help of host cell microtubules (51–54). Microtubules are dynamic structures in
all cells made of tubulin molecules. Microtubules have many responsibilities in the cell including
providing shape and trafficking throughout the cell by the motor proteins kinesin and dynein.
13

The motor proteins can associate with many factors that regulate processes within the cell. Both
proteins can carry cargo along microtubules with dynein moving towards the nucleus and kinesin
moving towards the periphery of the cell (54). The HIV-1 capsid core interacts with the
microtubule cytoskeleton to assist in uncoating, reverse transcribing the viral RNA, and
migrating toward the nucleus (51–53). The polar movement of the motor proteins could play a
role in HIV-1 uncoating, by pulling apart the capsid structure (31, 52). A knockdown of
microtubules within the host cell delays capsid uncoating. There are a few models suggesting
how uncoating occurs, but the exact process is not known (31). The HIV-1 capsid interacts with
microtubules but the capsid interaction with other cytoskeletal elements, such as actin, is also
being studied.
Though research has shown that HIV interacts more with microtubules, it also associates
with actin filaments. Microtubules are used more in long distance trafficking of HIV towards the
nucleus while actin trafficking is shorter distances (54). The microtubules generally are
important for cell division, creating intracellular pathways during interphase where the
microtubule motor proteins carryout mitotic processes. Microtubules are essential for metaphase
as they organize the chromosomes and pull apart the sister chromatid to ensure each daughter has
the same number of chromosomes (55). When HIV-1 infects a cell, it recruits microtubule
associated proteins that stabilize the microtubules and allow for trafficking to the nucleus (6).
The actin cytoskeleton is highly involved in cell communications, cell to cell signaling, and
movement of cells. Actin polymerization also occurs during phagocytosis and endocytosis at the
location to change the cell structure and plasma membrane to envelope the molecule (55). Actin
polymerization allows for cells to be motile with many of the processes requiring the myosin
motor protein.
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Actin knockdown has also shown a negative effect on HIV-1 infection (54, 56). Actin is
found in all eukaryotic cells at a high abundance. It consists of globular subunits that arrange in a
line to create the filamentous F-actin structure that creates actin bundles and networks (57). The
F-actin is linked by proteins that help form the essential actin structure. The network of actin is
highly involved in the structure of the cell, located just under the plasma membrane. Actin
organization within the cell allows the cell to keep its shape and participates in various cellular
processes such as trafficking of material (57). Actin organizing factors are important in
polymerization and function of the cytoskeleton. Actin may play a role in the cytoplasmic stages
of HIV-1 infection with the most prominent involvement in viral entry and budding, as those are
processes directly involve the plasma membrane.
The CD4 receptor and co-receptors are brought together on the host cell membranes by
actin (58). The binding of HIV-1 to the CD4 receptor on the host cell receptor causes
polymerization of actin at the binding location (59–61). Viral budding from the host cell
membrane or through a cell to cell transfer has high actin colocalization as well (58, 62, 63). The
actin motor protein, myosin, may move the HIV-1 complex within the host cell, though to a
lesser extent than the microtubule motor proteins (54, 64). Closer to the nucleus, smaller
movement of the viral complex occurs that is likely due to actin. Actin movement of viral
particles is smaller and may be an intermediate step before the virion is transferred to
microtubules (6, 59). During assembly and budding of virus, actin has been shown to help viral
proteins assemble at the host cell membrane (58). It is likely that actin is involved in more of the
HIV-1 infection stages (65). The network of the actin cytoskeleton is necessary for the survival
of the cell, but what exact role the associated proteins play in HIV-1 infection could provide
insight to the timeline of infection and replication within the host cell.
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SPTBN1 and HIV Infection
Proper actin polymerization within the cell is essential for efficient HIV-1 infectivity (66,
67). This thesis research focuses on the actin cytoskeletal element spectrin beta nonerythrocytic 1
(SPTBN1; (56)). SPTBN1 is a cellular factor associated with host cell membranes and the actin
cytoskeleton (68). SPTBN1 encodes for a filamentous beta-spectrin molecule that is found in
nonerythrocytic cells (69). Spectrin family proteins provide support and shape to cells by
interacting with the actin cytoskeleton as a scaffolding protein (56). Scaffolding proteins interact
with and organize different molecules, in this case actin. Spectrin molecules are polymers of
alpha (Fig. 4A brown) and beta spectrin (Fig. 4A yellow) molecules. The structure contains at
least 20 alpha spectrin repeats connected to at least 16 beta spectrin repeats to form a
heterodimer. This strand creates a tetramer with another heterodimer strand that aligns
antiparallel (68, 70, 71). Beta spectrin molecules have an N-terminal actin binding domain (Fig.
4A pink) and a varying C-terminal domain (Fig. 4A; (71)). The spectrin helices are connected by
a linker series (Fig. 4B). The helical structure allows the spectrin molecules to grow and shrink
based on what is necessary for the cell at the time (71).
The interaction of SPTBN1 with other host factors facilitates organization of the actin
network within the cell (72). A study by Brass in 2009 indicated that SPTBN1 is an HIVdependency factor or a protein required for HIV-1 replication that is expressed in the host cell
(68). The same study showed that knockdown of the SPTBN1 protein decreased the ability of
pseudotyped vesicular stomatitis virus G (VSV-g) HIV to infect HeLa cells (68). A pesudotyped
virus is made in the lab with a separate plasmid expressing a different envelope and a deletion of
the envelope gene from the viral genome. A common envelope used is the VSV-g protein
envelope. This pseudotyping prevents the HIV virus from infecting more than one cell due to the
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HIV envelope not being expressed, ensuring safety in the lab. VSV-g pseudotyped HIV has a
different mode of entry into the host cell, by endosome fusion rather than at the membrane.
Endosome fusion is where the HIV-1 virion enters the cell through an endosome that requires
acidification of the endosome to release the capsid into the cytoplasm of the host cell (73). The
involvement of HIV-1 with cytoskeletal elements and the indication that SPTBN1 alterations
affects HIV-1 infectivity, indicates the factor is involved in the HIV-1 replication process (56,
68, 74).
Another study by Gallo tested the infectivity variation with different viral envelope
proteins present, after SPTBN1 knockdown (74). The Gallo study did a knockdown of various
HIV-1 dependency factors involved in viral trafficking towards the nucleus, including SPTBN1,
and infected HeLa cells with wildtype or pseudotyped HIV-1 virus. The factors all decreased
HIV-1 infection with the wildtype envelope but only knockdown of Dynein Axonemal-Light
Chain 1 (DNAL1) and Microtubule Associated Protein 4 (MAP4) had the same decrease of
infection with the pseudotyped HIV-1 virus and were the main focuses of the study after that.
For the purposes of this thesis it is important to note that the Gallo study in HeLa cells showed
that siRNA knockdown of SPTBN1 did not decease infection of VSV-g pseudotyped HIV as
significantly as wildtype enveloped virus (74). This conclusion disagreed with a later study in the
Dai lab that had the same decrease of HIV infectivity in macrophages with wildtype or
pseudotyped virus (56, 74).
Further research has shown that SPTBN1 is a host factor that enhances HIV-1 infection.
Suppressing SPTBN1 decreased HIV-1 infection in macrophages (56). The research by Dai
focused on interleukin 27 (IL-27) as the inhibitor of SPTBN1 and a possible therapeutic
treatment for HIV-1 infection. IL-27 activates differentiation of monocytes into macrophages.
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Macrophages induced by IL-27 suppress SPTBN1 production and resist HIV-1 infection.
Macrophages that do not express IL-27 are susceptible to HIV-1 and HIV pseudotyped virus
infection (56). This research further supported the theory that SPTBN1 is required for HIV-1
infection of macrophages and may be an enhancing factor for infection in other primary cells.
SPTBN1 may work to enhance infection after fusion with the host cell and before reverse
transcription of the viral RNA is complete as it interacts with the matrix and capsid proteins (56).
The knockdown of SPTBN1 greatly disrupted the actin cytoskeleton and decreased HIV-1
infection (56). The role of SPTBN1 and HIV-1 protein interaction at early stages of HIV
infection may give a better idea of what is happening at those times.

Previous Research
Based on three previous studies, the Brass, Gallo, and Dai works, the cellular factor
SPTBN1 is involved in HIV-1 infectivity. Marc Havlicek, a previous graduate student in Dr.
Amy Hulme’s lab, showed that 38.7% knockdown of SPTBN1 decreased infectivity of HIV-1 by
37.58%. The SPTBN1 knockdown of 38.7% was the highest achieved. Marc Havlicek also found
that knockdown of SPTBN1 delayed uncoating in microglial cells by performing a CsA washout
assay. This indicates that SPTBN1 is involved in the uncoating step of HIV infectivity (75).

Aims and Hypotheses
This research will continue the research of Marc Havlicek to verify the effect of SPTBN1
knockdown on HIV-1 infectivity, examine the effect of SPTBN1 on viral fusion, and the
association of HIV-1 virions with the actin cytoskeleton after SPTBN1 knockdown. The first aim
of this research is to optimize the siRNA knockdown protocol of SPTBN1 and investigate the
effect on HIV-1 infectivity in microglial cells. Microglial cells are used because they are natural
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hosts for HIV-1 and are part of the viral reservoir that prevents curing HIV-1 infection. Initial
siRNA knockdown and qRT-PCR protocols will be enhanced through comparison of multiple
siRNA knockdown protocols and qRT-PCR reagent systems. After the optimized SPTBN1
knockdown procedure, the CHME3 microglial cell line will be infected with VSV-g pseudotyped
HIV-1 GFP reporter virus. The GFP reporter is added into the HIV-1 genome and expressed
when the virus infects a cell. The GFP expression represents the infectivity of the VSV-g-GFP
HIV virus. Infectivity of the virus will be calculated through flow cytometry to quantify infected
cells by GFP expression. The knockdown cells will be compared to a non-targeting siRNA
control. The microglial cells transfected with siRNA to knockdown SPTBN1 will be harvested
for RNA. The isolated RNA will be used for qRT-PCR to confirm the fold-decrease of SPTBN1
knockdown.
It is hypothesized that the down regulation of SPTBN1 in microglial cells will decrease
infectivity of HIV-1. Down regulation of SPTBN1 is shown in the Dai study to decrease
infectivity of HIV-1 within macrophages, as well as briefly discussed in the Brass and Gallo on
HeLa cells. Marc Havlicek’s research showed decrease infection with SPTBN1 knockdown in
the TCN14 microglial cell line, the daughter cell line of the CHME3 cells used in this project.
The second aim of this research is to investigate the role of SPTBN1 on viral fusion. A
knockdown of SPTBN1 will be done using the same methods as Aim 1, through siRNA
transfection. Synchronized viral fusion will be done by spinoculation of microglial cells with
VSV-g HIV-GFP reporter virus. During early time periods after infection, a viral fusion inhibitor
will be added to differentiate fused and unfused virus. This addition is done at various times to
look at the fusion overtime. The amount of GFP positive infected cells will then be quantified by
flow cytometry. It is hypothesized that the knockdown of SPTBN1 will decrease the ability of
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VSV-g HIV-GFP to infect microglial cells. The SPTBN1 knockdown has shown varied
decreases in infection using different pseudotyped virus within natural host cells and other cell
lines. SPTBN1 is an actin organizing protein that was identified in the Brass research as being
involved in the HIV infection process when using pseudotyped virus. The study by Gallo
contradicted this, showing that the knockdown of SPTBN1 knockdown affected wildtype HIV-1
enveloped virus more severely than VSV-g pseudotyped virus. This will verify if SPTBN1
knockdown decreases infection in VSV-g pseudotyped virus that enters the cell through an
endosome rather than at the membrane like wildtype HIV-1.
The third aim of this research is dependent upon the previous aims being complete and
time allotted. The third aim is to visualize the disruption, if any, of the actin cytoskeleton and
localization of HIV-1 with SPTBN1 knockdown during early replication stages. The siRNA
knockdown will used to decrease SPTBN1 expression and cells will be infected with the
fluorescently labeled HIV-GFP virus. The cells will be fixed at various times points, stained for
the actin cytoskeleton, and visualized by fluorescent microscopy. It is hypothesized that the
knockdown of SPTBN1 will disrupt the actin cytoskeleton in a way that changes the localization
of HIV-1 within microglial cells. The Dai study used fluorescence microscopy to visualize the
disruption of the actin cytoskeleton after SPTBN1 knockdown and determined a decrease in
infection. The past work of Marc Havlicek indicated an alteration in uncoating kinetics with
knockdown of SPTBN1. Because SPTBN1 is important for organizing the structure of actin, and
actin associates with HIV-1 during infection, disruption of actin will likely change the movement
of HIV-1 in early replication stages.
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Figure 1. HIV-1 Virion Structure.
The model is a representation of the HIV-1 virion and the placement of the proteins within it.
The viral membrane contains the gp120 and gp41 proteins with the matrix protein underneath the
membrane. The dark blue circles are the capsid proteins that surround the viral RNA genome in
yellow and the reverse transcriptase molecule in red (48).
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Figure 2. HIV-1 Replication Cycle.
A schematic of the replication cycle of HIV-1 virus. (Step 1) HIV-1 binds to the cost cell via an
interaction of the gp120 viral protein and the CD4 host cell receptor. (Step 2) Fusion of the virus
and host cell membranes fuse after a conformational change of the receptors. (Step 3) After the
capsid is released into the host cell, the capsid undergoes uncoating and reverse transcription of
the viral RNA occurs. (Step 4) The viral complex is imported into the nucleus where the viral
genome is integrated into the host cell genome. (Step 5) Transcription and translation of the new
viral genome occurs. (Step 6) The polyproteins congregate at the host cell membrane bud off.
(Step 7) The proteins are cleaved and organized to form the mature virion (48).
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Figure 3. Models of HIV-1 Uncoating.
Three models of HIV-1 capsid uncoating are discussed. The first model is cytoplasmic uncoating
where the capsid disassociates slowly as it moves toward the nucleus (left). The second model is
the nuclear pore complex (NPC) model where the capsid remains intact until it reaches the
nuclear pore (middle). The final model is the nuclear uncoating model where the entire capsid
enters the nucleus before uncoating occurs (right; (42)).
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Figure 4. SPTBN1 Structure.
(A) The beta-spectrin molecule is made of four subunits, two alpha (yellow) and two beta
(brown) subunits. (B) The tetramer makes helices that interact to create the spectrin network
connected by linker sequences (red; (71)).
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METHODS

Research Compliance
All research conducted was in accordance with continuing IBC protocols 2022-02.3 and
2022-02.4. The most recent update of these protocols was approved on 02/24/2022 (Appendix
A). Institutional Review Board approval was not required for human cell lines used in this
research. The 293T HEK cell line, derived from human embryonic kidney cells, was provided by
the Hope lab at Northwestern University. The CHME3 cells were a human microglial cell line
and provided by the Naghavi lab at Northwestern University (76).

Bioinformatics
Before experimentation could be performed the qPCR primers and siRNA targets were
acquired. The primers were ordered from IDT (www.idtdna.com) and tested previously for
accuracy of amplification (75). The siRNAs contained a four different sequences in the pools.
The siRNAs used were the ON-TARGETplus SPTBN1 pool, GAPDH pool, and non-targeting 4
(NT4) siRNAs were ordered from Dharmacon (Ref# SO-2963171G; horizondiscovery.com;
Table 1). Bioinformatics was done to determine the exact location the primers and siRNA target
on the specific genes. Using the NCBI database (blast.ncbi.nlm.nih.gov) the GAPDH and
SPTBN1 genes were searched and the intron and exon sequence was copied into a word
document for highlighting target locations. Each sequence from Table 1 was searched within the
document to determine the location the sequences recognized. The forward and reverse primers
should be localized to different exons with one intron between them. The primer sequences
should be smaller than about 24 nucleotides and have an amplicon size of less than 200
basepairs. The siRNA sequences should be in exons, within different parts across the gene to
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ensure an effective knock down. NCBI blast was also done on each sequence to ensure that it
was unique to either GAPDH or SPTBN1 genes.

Generating Plasmid DNA to Test Primer Efficiency
The pGEM plasmid has the GAPDH or SPTBN1 sequence inserted. The genes were
cloned into the pGEM-T Easy vector (Promega). The plasmids were isolated and used to test the
primer efficiency. Each plasmid was transformed into HB101 competent E. coli cells (Fig. 5;
Promega). The E. coli cells were thawed on ice and a 1:100 dilution of the stock plasmid was
made. To the thawed cells, 2 L of the diluted plasmid was added and chilled on ice for 10
minutes. The cells were heat shocked in a hot water bath at 42 C for 45 seconds before being
chilled on ice for 2 minutes. Using sterile technique 900 L of LB media was added to the cells.
The samples were put in the shaking incubator at 220 RPM for 1 hour at 37 C and LB-Amp
plates were prewarmed to 37 C. After the incubation, 100 L of the transformed cells were
plated on the LB-Amp plates and incubated overnight at 37 C (77).
Liquid E. coli cultures were made from the transformed cultures with 100 mL of LB
broth with 100 g/mL ampicillin concentration (Fig. 5). One colony from the transformation
plates was picked up and added to the flask. The cultures were incubated in the ThermoScientific
shaking incubator (Model 492) overnight at the same speed and temperature. The plasmid was
isolated from the E. coli using the Qiagen Plasmid Maxi Kit, according to the Qiagen protocol
(Fig. 5; (78)). The centrifugation for 30 minutes was done at 16,000 x g in the ThermoScientific
Sorvall RC6+ centrifuge and the sample was filter sterilized using cheese cloth to remove
precipitate. The supernatant was put on the equilibrated column and allowed to flow completely
through. After the remainder of the protocol was performed, the pelleted DNA was left upside
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down on a napkin to remove excess liquid and resuspended in 100 L elution buffer. The
plasmid samples were stored overnight at 4 C before being moved to -20 C until used.
The plasmid DNA was verified for the SPTBN1 and GAPDH genes by PCR and
restriction digest procedures (Fig. 5). PCR was done with the Maxiprep plasmid DNA, and the
appropriate primer set (refer to qPCR methods). The samples were then electrophoresed on a 1%
agarose gel with a 100 bp ladder as reference. As PCR controls, the previously used plasmid
DNA that was isolated via miniprep was electrophoresed as a positive control along with a water
sample with no DNA added as the negative control. Restriction digest was done using EcoRI
(New England Biolabs) and the samples were run on a 1% agarose gel with a 100 bp ladder.
Once verified the plasmid DNA was stored at 4 C for future use.

Maintaining 293T HEK Cells
The 293T HEK cell cultures were maintained on 10 cm tissue culture plates (Corning)
with enriched Dulbecco’s Modified Eagle Medium (DMEM; Ref# 10-017-CV), stored at 37 C
and 5% CO2. DMEM++ media was made with 500 mL of DMEM (Corning) warmed in the 37
°C water bath. Added to this was room temperature, 5 mL of 100X penicillin-streptomycinglutamine (PSG; Corning; Ref# 30-009-Cl) and 50 mL of fetal bovine serum to make 10% (FBS;
R&D Systems). The media was kept sterile by doing the procedure in the tissue culture hood and
stored at 4 C.
To split cells, the media was warmed to 37 °C in a hot water bath and the trypsin (0.05%
trypsin, 0.53 mM EDTA, 1X sodium bicarbonate; Corning Ref# 25-052-Cl) was set out at room
temperature. In the tissue culture hood, all materials were wiped down with 70% ethanol. An
existing 293T cell culture plate was used to make a new culture of cells. The old media was

27

aspirated off the cells and 1 mL of trypsin was added slowly to the side of the tissue culture
plate. The plate was gently tipped to ensure the trypsin covered the entire surface. The trypsin
was aspirated off the cells and one more milliliter of trypsin was added to the side of the plate.
The trypsin was aspirated off the cells and the plate of cells was placed in the 37 °C incubator for
2 minutes. While incubating, a new 10 cm plate was labeled. The trypsinized plate was removed
from the incubator and 10 mL of DMEM++ media was washed over the plate and pipetted up
and down gently to dislodge and break up clumps of cells. From the old plate, 1 mL of the cells
was added dropwise to the new plate with 10 mL of media. The new plate was gently rocked to
disperse the cells and placed back in the incubator. The remaining cells in media on the old plate
were aspirated off and the plate was placed in the tissue culture waste. The cells were maintained
at 60% to 80% confluence, with a new plate of cells being made if the cells were between that
range to keep a proper growth environment.

Making HIV-VSVG-GFP Virus
Virus was made in 293T cells using HIV-GFP and VSV-g plasmids, provided by the
Hope lab at Northwestern University. In 1 mL of DMEM media, 6 g of the HIV-GFP plasmid
and 4 g of the VSV-g plasmid was added along with 40 L of the transfection reagent
polyethylenimine (PEI; Polysciences) and mixed. The mixture was incubated at room
temperature for 15 minutes before being added dropwise to an 80% confluent plate of 293T cells.
The cells were put in the incubator and the next day, the media was changed to 10 mL of fresh
DMEM++ media.
The virus produced from the cells was harvested two days after transfection in the culture
hood. A 45 m filter (Millapore Sigma) was attached to a 20 mL syringe with the plunger
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removed. The filter was placed over a 50 mL conical tube and the media from the cells was
poured into the syringe with the filter attached. The plunger was replaced, slowly depressed to
filter all the media. The media from the 50 mL conical tube was stored in cryovials in 1 mL
aliquots at -80 °C.

Maintaining CHME3 Cells
CHME3 cells were maintained on a 10 cm tissue culture petri dish with CHME3 media
kept at 37 C and 5% CO2. CHME3 media used 500 mL of DMEM warmed to 37 °C, 25 mL of
FBS to make 5%, 1X PSG, and 5 mL 100 mM sodium pyruvate at room temperature (Corning).
To split cells, the CHME3 media was warmed in a 37 °C water bath and the trypsin was
set out at room temperature. The tissue culture hood and all materials were wiped down with
70% ethanol prior to the procedure. A plate of CHME3 cells was retrieved from the incubator to
make a new plate of cells. The cells were put into a new culture when at 60% to 80% confluence.
The old media was aspirated off the cells and 5 mL of 1X PBS was added to the side of the plate.
The PBS was aspirated off the cells and 3 mL of trypsin was added to side of the plate. The plate
was placed back in the incubator for 2-3 minutes. A new plate was labeled and 10 mL of
CHME3 media was added. The plate was retrieved from the incubator and gently tapped on the
sides to remove the cells from the bottom. In the tissue culture hood, 7 mL of CHME3 media
was added to the plate of cells and trypsin. The media was washed over the plate and pipetted up
and down to remove clumps of cells. From the old plate, 1.5 mL of cells in media was added
dropwise to the new plate with the media on it. The plate was gently rocked to disperse the cells
and placed back in the 37 °C incubator. The remaining cells in media from the old plate was
either used for plating cells for an experiment or aspirated off and the plate was discarded in the
tissue culture waste.
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Procedure for Plating Cells for siRNA Transfection
The CHME3 cells were maintained as explained previously and the extra cells were used
to plate in a 6-well plate. A hemocytometer was wiped off with ethanol and allowed to dry. The
cells remaining from an old plate were put in a conical tube. The tube was inverted three times
and 15 L of the cells were removed and placed on the hemocytometer. The Olympus CKX41
microscope was used to count all four quadrants that were averaged together and multiplied by
the dilution factor of 10,000 (79). The desired number of cells in each well for transfection was
1.7 x 105 cells in each well for a 6-well plate which was multiplied by the number of wells
needed. The total number of cells needed was divided by the number of cells in the remainder
from the plate of cells. The calculated value was the volume of the cultured cells needed in a
total volume equal to the number of wells plated times two. CHME3 media was added to the
cultured cells to volume. The tube of cells in media was inverted and 2 mL of the solution was
added to each well of a 6-well plate. The plate was gently rocked back and forth and placed in
the incubator.

siRNA Transfection Protocol
A day after the cells were plated in a 6-well plate, an siRNA transfection was done. The
cells were checked to be 60-80% confluent before transfection. The tissue culture hood was
wiped down with RNAaseZap (Invitrogen) as well as the p20, p200, p1000, rack for tubes, and
marker. The pipettes with tips and microcentrifuge tubes were placed in the tissue culture hood
and the hood was exposed to UV for 15 minutes. The GAPDH, SPTBN1, and NT (non-targeting
4) RNA duplexes (Dharmacon) were thawed on ice and the OPTIMEM (Corning) and
Lipofectamine RNAiMAX (Invitrogen) reagents removed from 4 C to be warmed to room
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temperature. The siRNA transfection was performed in the hood, starting with two Eppendorf
tubes for each sample. The transfection reagent and siRNAs were diluted with media with the
following amounts, tube 1 had 50 L of OPTIMEM with 4 L of lipofectamine RNAiMAX
added. In tube 2, 100 L of OPTIMEM was combined with 3 L of either GAPDH, SPTBN1,
NT, or no siRNA for a 100 pmol concentration, and the tubes were gently tapped to mix. These
volumes were used for one reaction in one well. Both tubes were incubated at room temperature
for 5 minutes. The tube 1 content was added to the tube 2, mixed by pipetting, and incubated at
room temperature for 20 minutes.
The media on the cells was aspirated off and 1 mL of OPTIMEM was added to the side
of each well. The siRNA mixture was added to the appropriately labeled well dropwise. The
plate was gently rocked back and forth and placed in the incubator. Four hours after the
transfection the media on the cells was aspirated off and 1 mL of DMEM without PS, warmed in
the 37°C water bath, was added to the side of the well. The next day the media was aspirated off
and 2 mL of warmed CHME3 media was added to the side of each well for later RNA isolation
or replated into a 96-well plate for infection.

New Lipofectamine RNAiMAX Transfection Protocol
The day before transfection, the cells were plated to have 60-80% confluency at
transfection. The tissue culture hood, p10, p20, p200, p1000, rack for tubes, and marker were
wiped down with RNAaseZAP and placed in the hood. The microcentrifuge tubes and pipette
tips were placed in the hood before exposing it to UV for 15 minutes. The RNA duplexes,
SPTBN1, GAPDH, and NT were thawed on ice. The OPTIMEM and lipofectamine were
removed from the fridge. CHME3 media was warmed to 37 °C. The transfection procedure was
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done according to the standard Lipofectamine RNAiMAX transfection protocol from Invitrogen
for 2.5 x 105 cells per well. The stock of the RNA duplexes was 20 M with 1.5 L used to make
the 30 pmol concentration (80). The cells were replated the following day into a 96-well plate for
infectivity and one 6-well plate was used for RNA harvesting two days after transfection to
determine SPTBN1 expression.

RNeasy RNA Purification
Total RNA was isolated and purified from the transfected CHME3 cells using the Qiagen
RNeasy Plus Mini kit and protocol (78). The media was removed from the transfected cells and 1
mL of 1X PBS was added to the side of the well. The PBS was aspirated off and an in-well lysis
was performed using a mixture of 10 L -mercaptoethanol for each 1 mL of RLT buffer. For
the 6-well plate, each well received 350 L of the buffer RLT--mercaptoethanol solution. The
solution was left to sit briefly before the tip of a pipette was used to dislodge the cells from the
surface of the wells. The cell solutions were added to a microcentrifuge tube and homeogenized
by vortexing breifly. The lysates were pipetted onto a QIAshredder spin column to homogenize
the sample. The run through was transferred to a gDNA Eliminator column to remove gDNA.
Into the collection tube with the run through, 350 L of 70% ethanol was added, and the
procedure continued. After the wash procedures, the run through was discarded in the waste
container and a new collection tube was placed on the column to remove any extra wash buffer.
The RNA was eluted off the column with the addition of 50 L of nuclease-free water. The
columns were discarded, and the samples were placed in the -20°C freezer until PCR was
performed.
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SsoFast qPCR
The Bio-Rad SsoFast EvaGreen qPCR Supermix procedure was compared to the iTaq
One Step Kit for earlier detection and accuracy (81, 82). The SsoFast reactions were 20 L each
including 0.5 M each of the forward and reverse primers and 1 L of the DNA sample (Table
1). The thermocycler used was a Bio-Rad CFX model with the parameters set in the protocol
(81). The initial holding stage was 95 C for 30 seconds before the cycling began. The cycle
stage of qPCR contains two steps, one at 95 C for 5 seconds and one at 60 C for 5 seconds. The
plate was read after each cycle to determine at what cycle PCR product was amplified. The cycle
number that product was amplified was the CT value. The cycling stage was repeated 45 times
(Fig. 6). After all the cycles are complete there was a melt curve as the final step that determines
at what temperature the product strands melt from each other. The desired products should have
the same melting temperature and was used to verify no contamination (Fig. 6).

iTaq One Step qPCR
Quantitative PCR (qPCR) or quantitative reverse transcription PCR (qRT-PCR) was
performed using the Bio-Rad iTaq Universal SYBR Green One Step Kit protocol (82). The
reaction totals were 20 L each including 1 L sample DNA or RNA and 0.3 M each of the
forward and reverse primers, either GAPDH or SPTBN1, as well as the supermix (Table 1). The
thermocycler used was a Bio-Rad CFX model with the parameters set in the protocol. The
reverse transcriptase step was at the beginning of the qPCR procedure being 50 C for 10
minutes to make the RNA sample into cDNA. The holding stage was 95 C for one minute. The
cycling stage included two steps, one at 95 C for 10 seconds and one at 60 C for 30 seconds.
The cycle was done 45 times and a melt curve was added at the end the same as the SsoFast
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protocol (Fig. 7). This procedure was done for determining the knockdown amount and the
primer efficiency.

Pfaffl Method to Analyze qRT-PCR
Primer efficiency was performed by doing qPCR with seven dilutions of genomic DNA
to make a standard curve. The Pfaffl efficiency and quantification of knockdown was done as
described in the Essential Laboratory Techniques (Unit 10.3.33, Current Protocols; (83)). The
Pfaffl efficiency was determined using the slope of the standard curve plus one (Fig. 8). The
Pfaffl method uses the change in CT value determined by subtracting the experimental CT value
from the non-targeting control CT value. The Pfaffl efficiency was taken to the power of the
change in CT value of the gene to determine the fold change between samples. The fold change
between the target samples (SPTBN1) were divided by the fold change of the housekeeping gene
(GAPDH) samples. This determined the normalized fold change of the knockdown (Fig. 18).

Infecting with Virus
The day after the CHME3 cells were transfected with siRNAs, the cells were replated in a
96-well plate. The procedure on the 6-well plate was the same as maintaining the CHME3 cells
with washes of 1X PBS before the cells were trypsinized. Once the cells were removed from the
bottom of the plate, each separate transfection reaction was put into a conical tube. Using a
hemocytometer, the cells were counted, and the calculation was done to determine the volumes
of cells and media needed to plate 6,000 cells in each well of a 96-well plate. The cells were
plated for the number of reactions to be performed and the plate was put back in the incubator.
The following day, the cells were infected with virus. A dilution series of virus was done
initially to determine the proper virus concentration to use. Before the virus was added, the
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media on the cells was changed to CHME3 media soon after removed from 4 °C fridge, with 1
µL polybrene for every 2 mL media (1X). The first reaction wells were changed to CHME3
media with 1 µL polybrene for every mL media (2X). From the thawed virus vial, 100 µL was
added to the first row that had the 2X polybrene media. A serial dilution was made by adding
100 µL from the first well to the next well and so on, leaving the last two wells without virus as
negative infection controls. The plate was then spinoculated in the ThermoScientific centrifuge
(Ref: 75004261) at 1,200 x g at 16 °C for one hour to synchronize infection. Immediately after
the centrifugation was completely, the media was replaced on all the wells to 200 µL CHME3
media and the plate was placed back in the incubator. The next day the media was replaced again
with CHME3 media at 37 °C.
The final day was fixing the cells before flow cytometry could be done. The media on the
96-well plate was removed and cells were washed with 1X PBS. The cells were trypsinized with
100 µL and put in the incubator for 5 minutes, until the cells came off the bottom of the well.
The cells were resuspended in the trypsin. The cells were fixed using 100 µL of a 1:1
paraformaldehyde and 1X PBS solution. The plate was parafilmed, covered in aluminum foil,
and put at 4 °C until flow cytometry.

Flow Cytometry to Deterime Viral Infectivity
Infectivity was assessed by flow cytometry to find the percent GFP positive cells that
indicated HIV-GFP infection. Each well was resuspended before flow cytometry was performed.
The software was turned on and instructions followed on the Accuri C6 flow cytometer (BD
Biosciences). The template was selected with the parameters set to 10,000 events or 80 µL limit,
and fast run speed. As each sample was tested, they were named based on the virus dilution and
siRNA transfection reaction. Plot 1 of the template displayed the live cell count and the
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percentage of particles that were live cells as opposed to cell debris. Plot 2 of the template
displayed the percent of the cells that expressed GFP. After all samples were run, the uninfected
or no virus samples for each siRNA transfection condition were used to set the GFP fluorescence
threshold to between 0.01-0.0%. In an excel file the data was collected to have plot 1 as percent
and count of live cells and plot 2 had percent of infected cells. After all samples, the flow
cytometer was shut down based on the instructions.

Viral Fusion Assay
A viral fusion, ammonium chloride add-in assay was done to determine the amount of
fusion overtime. An initial fusion assay was done with various concentrations of ammonium
chloride, 10 mM, 25 mM, 50 mM, and 100 mM. CHME3 cells were plated at 6,000 cells per
well on a 96-well plate. The following day, the cells were infected in the presence of ammonium
chloride. A 1/100th dilution of virus was used with the ammonium chloride concentrations in
CHME3 media also containing 1X polybrene. The media and virus media were placed on the
cells and spinoculation was performed to synchronize fusion at 16 C 1200 x g for 1 hour. After
the spin, the media on the cells was changed to CHME3 media with the corresponding
ammonium chloride concentration. The next day the media was changed to CHME3 media
without ammonium chloride. The cells were harvested as previously described in the infecting
with virus section. Flow cytometry was performed as described in the testing infectivity section
of the methods to determine the number of cells infected with the various concentrations of
ammonium chloride.
The following fusion assays used the 10 mM ammonium chloride (NH4Cl) concentration.
Master mixes were made for the constant NH4Cl samples and no virus controls. The
corresponding media mix was added to the samples, all other wells had CHME3 media with
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virus and polybrene as previously stated. The plates were spinoculated and immediately after
removing from the centrifuge the media on the wells was changed to 200 L CHME3 media or
10 mM NH4Cl CHME3 media for the NH4Cl constant reaction and 0 hour time point. At 15, 30,
45 minutes, 1, 2, 3, and 4 hours following infection, the media on the corresponding wells was
changed to NH4Cl media. In between time points the plates were kept in the 37 C incubator and
the NH4Cl media was warm in the 37 C bead bath. The following day all of the media on the
samples was removed and replaced with 100 L CHME3 media. The cells were harvested as
previously described two days following infection and stored at 4 C until flow cytometry was
performed.

Half-life Calulations
Fusion assay results were normalized to the maximum infection of that siRNA
transfection reaction and was used to determine the half-life of fusion. To find the half-life time,
the two time points on either side of 50% were graphed separately. An equation of the line made
by those points was found and 50 was plugged in for y. The value of x was solved for and
indicates the time in hours it took for half of the HIV virus to fuse with the cells in that sample.
This hour time was converted to minutes and seconds. An average time from three independent
experiments was found and a two tail independent t-test was done to determine if there was a
statistical significance between the half-life of HIV fusion in SPTBN1 and NT siRNA
transfected cells. The analysis was done through SPSS comparing the fusion half-life times for
the SPTBN1 and NT knockdown samples.
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Table 1. Primer and siRNA Sequences
Sequence
SPTBN1

GAPDH

Non-targeting

Forward
Primer

GCACACTACATTTGA
GCATGAC

GCACCGTCAAGGCTGA
GAAC

N/A

Reverse
Primer

GTTCTCGCGCTTCTG
GATA

GCCTTCTCCATGGTGG
TGAA

N/A

siRNA
Target 1

CGGAAGAGAUCGCC
AAUUA

GUCAACGGAUUUGGU
CGUA

N/A

siRNA
Target 2

GACGAGAUCUUGUG
GGUUG

CAACGGAUUUGGUCG
UAUU

N/A

siRNA
Target 3

CUUAUGUGGUGACU
UAUUA

GACCUCAACUACAUG
GUUU

N/A

siRNA
Target 4

CGAGUGCAAUGAAA
CCAAA

UGGUUUACAUGUUCC
AAUA

AUGAACGUGAAU
UGCUCAA

Figure 5. Growing up new plasmid DNA.
Plasmid DNA with either GAPDH or SPTBN1 gene present was transformed into competent E.
coli, grown in liquid media in the presence of an antibiotic, and from that culture the plasmid
DNA was isolated via Maxiprep. The plasmid DNA was confirmed for the genes by restriction
digest and PCR that was run on a gel.
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Figure 6. SsoFast EvaGreen Protocol.
The qPCR protocol was set up and ran on a Bio-Rad CFX thermocycler included a holding stage
and cycle stage to amplify the desired product. Screen grab from Bio-Rad COX manager
software.

Figure 7. iTaq SYBR Green Protocol.
The qPCR was performed on a Bio-Rad CFX thermocycler. This protocol included a reverse
transcription step, holding stage, cycling stage, and a melt curve procedure. Screen grab from
Bio-Rad COX manager software.
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Figure 8. Pfaffl Knockdown Calculation.
The equation to determine the normalized fold change of gene expression is stated. The primer
efficiency based on the iTaq Universal SYBR Green One-Step Kit for GAPDH and SPTBN1
primers is 0.62 and 0.79 respectively (see primer efficiency results).
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RESULTS

Bioinformatics
Bioinformatics using NCBI was done to determine where the primers and siRNAs
targeted within the SPTBN1 and GAPDH genes. SPTBN1 has 36 exons (Fig. 9A) with the
siRNAs targeting exon 8 (blue), exon 14 (orange), exon 16 (green), and spanning exon 21 and 22
(purple; Fig. 9B). The forward primer for SPTBN1 binds at the end of exon 26 and the reverse
primer binds within exon 27 (Fig. 9C). The qPCR primers amplify a sequence of 127 basepairs.
NCBI Blast of siRNA and primer sequences indicate uniqueness to SPTBN1 mRNA transcript 1.
Bioinformatics was done on the GAPDH gene in the same manner as SPTBN1. GAPDH
has 9 exons with siRNAs targeting four locations (Fig. 10A and B). Two siRNAs spanned two
exons, exon 2 and exon 3 (blue and purple). Another siRNA targeted an area in exon 3 (green)
and one in exon 4 (orange; Fig. 10B). The forward GAPDH primer recognizes a sequence in
exon 4 and the reverse primer recognizes exon 5 (Fig. 10C). The qPCR primers amplify a
sequence of 151 basepairs. NCBI Blast of the GAPDH primer and siRNA sequences showed
they were unique for GAPDH mRNA transcript 1.

qRT-PCR Protocol
Two qRT-PCR protocols were compared, SsoFast EvaGreen Supermix that was used
previously and iTaq Universal SYBR Green One-Step Kit, a new kit. To quantify RNA samples,
qRT-PCR was preformed to get a quantitative cycle number (Cq) that represents at what cycle
the sample was amplified. The qRT-PCR protocol was optimized because it was done in all
future experiments. A serial dilution of plasmid DNA and no DNA control was used with both
qPCR kits to determine which protocol to use. The qPCR was done with the SPTBN1 and
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GAPDH primer sets. A smaller Cq value indicates the sample was amplified at a lower cycle
number. The iTaq One-Step Kit amplified the plasmid DNA three cycles sooner for both primer
sets (Table 2). The iTaq One-Step Kit had greater Cq values in the no DNA sample which was
the background level of amplification. Because the earlier amplification of the sample and less
background with the iTaq One-Step Kit, it was used for the remainder of qRT-PCR procedures.
With the protocol determined, the primer efficiency with the kit had to be determined.

Primer Efficiency
The primer efficiency of SPTBN1 and GAPDH primer sets was determined using
plasmid DNA dilutions and qPCR. A serial dilution of the plasmid DNA with SPTBN1 sequence
was made with seven dilutions. The DNA dilutions were quantified by qPCR in triplicate. The
initial dilutions made were 5 L of plasmid DNA in 45 L water. The results were not evenly
spread which is desired of a serial dilution (results not shown). Because the results were not what
is expected from a serial dilution. A larger dilution volume was used.
The second dilution of plasmid DNA made used 20 L sample in 180 L water with the
qPCR results shown in the amplification curves (Fig. 11). The Cq values of five dilutions was
used to make the standard curves (Table 3 and Fig. 12). The standard curve shows the equation
of the line and the R2 value that indicates how well the equation represents the data. An Rsquared value above 0.99 was desired to show the equation was accurate. The equation [10^(1/slope) -1] was used to determine the primer efficiency. The same procedure was done in
duplicate to verify the results. The first run had a primer efficiency of 0.55 and the second run
had a primer efficiency of 0.53.
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The calculated primer efficiencies for SPTBN1 with the iTaq One-Step Kit (0.53 and
0.55) were much lower than the primer efficiency with the SsoFast EvaGreen supermix kit used
previously in the lab, obtained by Marc Havlicek (1.05). Due to the lower efficiency,
optimization was done to increase the primer efficiency. The SPTBN1 primer sets were rediluted
from the stock primers and used at a higher concentration to ensure the primer amount was not
limiting the sample amplification. The primers were being used at 0.3 M concentration and this
was increased to 0.5 M concentration. The standard curve from this data was not the desired
result (Fig. 13). The R2 value was low at 0.8178 meaning that the equation for the line could not
be trusted.
Next, the plasmid DNA was regrown and isolated for the serial dilution. The plasmid
DNA was transformed into E. coli, grown up in liquid culture, isolated using a Maxiprep, and
verified by PCR and restriction digest. The PCR was performed with the SPTBN1 and GAPDH
primers on the previous plasmid DNA (mini), the newly isolated plasmid DNA (maxi), and a
water sample as a negative control (Fig. 14). The SPTBN1 primers should amplify a product of
127 basepairs and the GAPDH primers should amplify a product of 151 basepairs. The SPTBN1
mini and maxi samples had product amplified between 100 and 200 basepairs as compared to the
known ladder. The GAPDH mini and maxi samples had product between 100 and 200 basepairs
and was slightly higher on the gel than the SPTBN1 products (Fig. 14). Based on the PCR
results, the SPTBN1 and GAPDH sequences were within the plasmid DNA.
A restriction digest was also done to further confirm the genes in question were present.
There were cut sites for the EcoR1 restriction enzyme on either side of the inserted genes,
SPTBN1 and GAPDH. The product sizes were expected to be the same as the PCR products. The
SPTBN1 sample had product between 100 and 200 basepairs. The GAPDH sample had product
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slightly higher than the SPTBN1 on the gel meaning the GAPDH product was slightly larger
than SPTBN1 (Fig. 15). This was a second verification that the SPTBN1 and GAPDH genes
were within the newly isolated plasmid DNA. This plasmid DNA was used for the remainder of
the primer efficiency experiments.
With the new plasmid DNA verified for the SPTBN1 and GAPDH genes, the primer
efficiency procedures were continued. A new 1:10 dilution series of the SPTBN1 plasmid DNA
was done as previously. The qPCR results of two runs of the new plasmid DNA dilution had a
calculated primer efficiency of 0.84 and 0.74 (Table 4). These runs had efficiencies closer to the
previously calculated SsoFast primer efficiency. An average of the two runs was 0.79 and used
as the SPTBN1 primer efficiency for determining knockdown of the gene.
The GAPDH primer efficiency was determined with the same procedure as the SPTBN1
primer efficiency using the GAPDH primer set with the plasmid DNA from the Maxiprep (Fig.
14 and 15). The Cq values for the five dilutions were used to make a standard curve (Table 5 and
Fig. 16). The qPCR of the serial dilution was done twice to verify the results. Each time the
standard curves had R-squared values greater than 0.99 (Fig. 16). The primer efficiency for both
runs was 0.62 (Table 5 and Fig. 16). Because both runs had the same calculated efficiency, the
GAPDH primer efficiency of 0.62 was used for the knockdown calculations.

Comparison of Two siRNA Knockdown Protocols
After the primer efficiencies were calculated, siRNA knockdowns of SPTBN1 were
performed. Knockdown of SPTBN1 was performed by siRNA transfection to decrease the
expression of the protein. Knockdown was also done on GAPDH initially to verify the procedure
worked to decrease protein levels. Following siRNA knockdown, the RNA was isolated from
the cells and quantified by qRT-PCR using SPTBN1 and GAPDH primers. The qRT-PCR curves
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indicate at what cycle the RNA product was amplified and represents the amount of RNA
product present in each sample (Fig. 17). Based on what cycle the samples were amplified, the
change in expression of SPTBN1 can be determined using the Pfaffl calculation method with
primer efficiencies previously determined.
The Pfaffl method compares the change in RNA levels of a gene in question to a
housekeeping gene (like GAPDH) where the levels should not change. Two siRNA knockdown
protocols were compared to determine the most efficient procedure, with the greatest decrease of
SPTBN1 RNA. The change in SPTBN1 RNA level was determined by subtracting the cycle
number (CT) that SPTBN1 primers amplified product in the SPTBN1 knockdown experiment
from the non-targeting siRNA experiment (Fig. 18). The Pfaffl efficiency was used as the base to
the power of the change in CT value. This calculation was done with both SPTBN1 and GAPDH
primer sets. The normalized RNA fold change was calculated by dividing the end value for the
SPTBN1 primers by the GAPDH end value. This represents the percent expression as a decimal
of SPTBN1 (Fig. 18).
The expression level of SPTBN1 was determined using the method described above for
two siRNA knockdown protocols. A protocol used by previously in Dr. Hulme’s lab was
designated the old knockdown protocol and the RNAiMAX protocol was designated the new
knockdown protocol. The old knockdown protocol resulted in 83.5% expression of SPTBN1,
and the new protocol resulted in 11.5% expression of SPTBN1 (Fig. 18 and 19). This can also be
stated as the old protocol caused a 16.5% decrease of SPTBN1 expression while the new
protocol caused an 88.5% decrease of SPTBN1 expression. The new siRNA knockdown protocol
was more efficient at knocking down SPTBN1 compared to the old knockdown protocol. A
greater decrease of SPTBN1 expression was desired to see the effect of the absence of SPTBN1.
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Therefore, the new protocol was used when determining the change in infectivity after siRNA
knockdown.

Effect of SPTBN1 Knockdown on HIV Infectivity
The new siRNA knockdown protocol was performed on CHME3 cells to decrease
SPTBN1 expression, after which the cells were infected with HIV. Previous publications show
that SPTBN1 knockdown decreases HIV infection with varying significance depending on the
cell types and virus used (56, 68, 74). The new knockdown protocol was performed twice with
infection afterwards. The expression of SPTBN1 in the first infectivity assay was 29% or a 71%
decrease of expression (Fig. 20). The cells were infected with eight dilutions of HIV-GFP virus
and infectivity was determined by flow cytometry (1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128, and
1/256). The infectivity results were normalized to the non-targeting siRNA knockdown control at
100%.
The first knockdown (10/13/21) and infectivity experiment resulted in infection after
SPTBN1 knockdown remaining relatively the same as the non-targeting knockdown. The 1/8th
and 1/16th dilutions had slight decreases in infection. The 1/64th, 1/128th, and 1/256th dilutions
had slight increases in infection after SPTBN1 knockdown and the remaining dilutions had the
same amount of infection (Fig. 21). The same procedure was repeated to verify the results.
The second siRNA knockdown with the new protocol (10/26/21) had 7% expression of
SPTBN1 or 93% decrease expression (Fig. 20). This was the greatest decrease in SPTBN1
expression that the new knockdown procedure achieved. The infectivity results showed that at
every dilution of virus, infectivity increased with the SPTBN1 knockdown compared to the nontargeting knockdown (Fig. 22). This was the opposite of previous published results and what the
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previous graduate student achieved with the old siRNA knockdown protocol. Because of this, the
old knockdown protocol was performed twice to try to achieve the previous results.
The old protocol siRNA transfection was performed twice with infectivity following. The
first run of knockdown (3/8/22) resulted in 31% SPTBN1 expression or 69% decrease expression
(Fig. 20). The infectivity resulted in decrease of infection among all the virus dilutions (Fig. 23).
The procedure was performed again to verify the results. The second time with the old
knockdown protocol (3/27/22) resulted in 8% SPTBN1 expression or 92% knockdown of
SPTBN1 (Fig. 20). This was similar to the highest knockdown achieved for the new protocol.
The resulting infectivity had a decrease of infection with SPTBN1 knockdown with the 1/32nd
dilution and smaller (Fig. 24). The 1/2nd dilution caused an extreme increase in HIV infection.
The 1/4th, 1/8th, and 1/16th dilutions had small increases in HIV infection (Fig. 24). With the
decrease in HIV infectivity with SPTBN1 knockdown shown with the old siRNA transfection
protocol, it was used for all other knockdown procedures.

Fusion Assay
Fusion kinetics were next investigated by adding a fusion inhibitor to infected cells
overtime. These cells had SPTBN1 or NT siRNA transfection to see if SPTBN1 knockdown
alters fusion. The NT siRNA should not target anywhere in the genome and therefore should not
alter fusion but is a control for adding siRNA to the cells. To determine the proper fusion
inhibitor, ammonium chloride (NH4Cl), concentration to use, a fusion assay was performed with
various concentrations (10 mM, 25 mM, 50 mM, and 100 mM). New ammonium chloride was
filter sterilized and used at the varying concentrations. One sample used 25 mM concentration
old ammonium chloride for comparison to the new NH4Cl. The infection percent was determined
with flow cytometry and shown as percent GFP+ cells. All concentrations of ammonium chloride
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had infection rates less than 0.45% (Fig. 25). The no treatment sample had 46% infection. The
100 mM ammonium chloride sample had the lowest rate of infection, but lower cell counts. The
10 mM concentration sample was also very low infection at 0.15% and the cells tolerated the
ammonium chloride better (Fig. 25). Therefore, 10 mM ammonium chloride was used for all
other ammonium chloride fusion experiments.
With the concentration of ammonium chloride determined, a fusion assay was performed
to determine the kinetics of fusion in CHME3 cells. Ammonium chloride media was added in at
various times after infection (0 hour, 15, 30, 45 minutes, 1, 2, 3, and 4 hours) and infectivity was
determined by flow cytometry. The line made by the data points had a big increase of infection
within the first hour and lesser but steady increase in infection from 1 to 4 hours (Fig. 26). This
result was similar to the fusion kinetics of other cell lines (84, 85).
With fusion kinetics determined in cells with no expression changes, a knockdown of
SPTBN1 was done to see how it affects fusion. The knockdown percentage achieved was 86%
decrease in SPTBN1 expression (Fig. 27). The fusion results showed that in the first half an
hour, fusion kinetics for SPTBN1 and NT transfection cells had the same fusion rate. From the 1
hour to the 4-hour post infection time point, SPTBN1 knockdown had a decreased rate of HIV
infection compared to NT (Fig. 28). The Infection rates for all of the conditions was above 50%
which may be inaccurate due to the increased probability of two or more viruses infecting one
cell. The infection percent desired is below 50%, so a new stock of CHME3 cells were thawed,
and the experiment was performed again.
The new CHME3 cells were used in a fusion assay as done previously. New virus was
used at a concentration of 1 microliter in 100 L from a stock made by Emma Wise. The
knockdown percentage was determined to be 94% decrease of SPTBN1 expression or 6%
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expression (Fig. 27). The fusion kinetics showed that SPTBN1 had more fusion in the first 15
minutes of the assay and kinetics were the same at the 30-minute time point. From the 45-minute
time point on, the SPTBN1 knockdown cells had a slightly lower infection rate compared to the
NT transfected cells (Fig. 29).
The fusion assay procedure was done once more to confirm the results. The knockdown
achieved from this experiment was 81% knockdown (Fig. 27). The fusion kinetics of SPTBN1
and NT were compared and exhibited the same fusion rate for the first 45 minutes. After 45
minutes, the NT fusion increased to above 25% infection before leveling off while SPTBN1
fusion leveled off at just above 20% infection (Fig. 30A). To make sure the lower overall
infection of SPTBN1 knockdown cells was not causing the change between the samples, the
values were normalized to the highest percentage of infection for the respective samples. This
was graphed comparing SPTBN1 and NT samples with the normalized fusion curves being
closer than the unnormalized values (Fig. 30B). SPTBN1 had a slightly lower infection at the 3hour time point with all other times being close to the NT infection. The half-life of HIV fusion
for the three experiments was calculated for statistical analysis.
Each experiment was normalized by setting the highest fusion to 100% (Fig. 30B). Using
the normalized values for each experiment, the time where 50% of HIV had fused in the sample
was determined as the half-life. The half-life from the 7-7-22 experiment was 9 minutes and 22
seconds for SPTBN1 and 11 minutes and 57 seconds for NT samples. The 9-2-22 fusion
experiment found the half-life for SPTBN1 samples to be 13 minutes 45 seconds and NT was 22
minutes 55 second. The final experiment on 9-16-22 determined the half-life of SPTBN1
samples to be 25 minutes and 15 seconds and NT 25 minutes and 26 seconds (Table 6). From
these three independent experiments, the average half-life of fusion in SPTBN1 knockdown cells
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was 16 minutes and 7 seconds and the average half-life of fusion NT knockdown cells was 19
minutes and 10 seconds. The standard error was determined and along with the average time was
used in a t-test calculation. The p-value was determined to be 0.648, meaning the average halflife values were not statistically different between siRNA knockdown and control cells.

Table 2. Comparison of qPCR from Two Supermixes
SsoFast EvaGreen Supermix

iTaq Universal SYBR Green One-Step
Kit

Plasmid
DNA
Dilution

GAPDH Primers
Cq Average

SPTBN1 Primers
Cq Average

GAPDH Primers
Cq Average

SPTBN1 Primers
Cq Average

105

24.40

23.81

21.60

21.01

104

17.88

20.16

14.97

17.77

103

14.60

14.37

11.44

11.70

No DNA

38.67

34.80

38.98

36.90

Table 3. Initial SPTBN1 primer efficiency qPCR values
Plasmid DNA Dilution

Initial Run (11-29-2021) Cq
Values

Second Run (11-30-2021) Cq
Values

105

9.37

8.97

104

14.73

15.34

103

20.62

21.79

102

25.92

26.52

101

30.06

30.22

Primer Efficiency

0.55

0.53
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Table 4. Final SPTBN1 primer efficiency Cq values
Plasmid DNA Dilution

(1-24-2022) Cq Values

(1-27-2022) Cq Values

105

9.85

11.03

104

12.49

14.51

103

16.14

18.52

102

20.28

23.44

101

24.80

27.44

Primer Efficiency

0.84

0.74

Table 5. GAPDH primer efficiency Cq values
Plasmid DNA Dilution

(1-24-2022) Cq Values

(1-27-2022) Cq Values

105

13.56

13.45

104

17.29

17.59

103

22.28

22.65

102

27.00

28.04

101

32.46

32.21

Primer Efficiency

0.62

0.62
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Table 6. Half-life of HIV fusion
Half-life of fusion (min)*
Infection Date

SPTBN1

NT

SPTBN1 Knockdown

7-7-22

9:22”

11:57”

85.7%

9-2-22

13:45”

22:55”

93.8%

9-16-22

25:15”

25:26”

80.8%

Average Time

16:07”

19:10”

Standard error

4.74

3.92

*Data difference not statistically significant.

Figure 9. SPTBN1 Primer and siRNA Locations.
NCBI results of the SPTBN1 gene shows the introns and exons with the targets indicated. The
exons are green vertical lines and introns are the horizontal lines connecting them for SPTBN1
(A). The siRNA target locations are shown along with the exon where the target recognizes with
a bracket (B). Arrows and a star (spanning two exons) indicate where the target exons are in the
entire gene. The forward and reverse primer sequences amplify within two exons shown by
arrows with a larger image of where (C).
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Figure 10. GAPDH Primer and siRNA Locations.
The GAPDH gene schematic was obtained through an NCBI search. The exons are thicker green
boxes, and the introns are the lines between the exons (A). The siRNA target locations and exon
number targeted are indicated by a bracket and color coordinated (B). Arrows and stars show the
target exons in the entire sequence. The forward and reverse primer targets are enlarged with
arrows showing the exon parts amplified (C).
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Figure 11. qPCR Amplification Curve.
The primer efficiency amplification curves from qPCR on 11-29-2021 with the SPTBN1 primers
and the larger dilution volume. Relative fluorescence unit (RFU) indicates the level of
fluorescence.

Figure 12. Standard Curve for 11-29-2021 qPCR Primer Efficiency.
A standard curve was made using the average Cq value of triplicate qPCR results from a serial
dilution of plasmid DNA containing SPTBN1. The equation of the line and R-squared values for
the data are present.
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Figure 13. Standard Curve for 12-9-2021 qPCR SPTBN1 Primer Efficiency.
A standard curve was made using the Cq values of a serial dilution of plasmid DNA with the
SPTBN1 gene present. The dilution was done in triplicate and the average values used as the
data points.

Figure 14. PCR Verification of Plasmid DNA.
PCR was performed on the Maxiprep isolated plasmid DNA with GAPDH or SPTBN1 genes
present with the appropriate primers. The PCR samples were run on a gel to visualize the product
sizes compared to a 100 bp ladder. TRIM was a sample separate from this thesis research.
SPTBN1 expected size was 127 basepairs. GAPDH expected size was 151 basepairs.
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Figure 15. Restriction Digest Verification of Plasmid DNA.
The restriction digested newly isolated plasmid DNA with either GAPDH or SPTBN1 was ran
on a gel to verify the product size. The product sizes were compared to a 100 bp ladder. TRIM
was a sample separate from this thesis research. SPTBN1 expected size was 127 basepairs.
GAPDH expected size was 151 basepairs.

Figure 16. Standard Curve for 1-24-2022 GAPDH Primer Efficiency.
The Cq values from the 1-24-2022 GAPDH plasmid DNA serial dilution qPCR results were used
for a standard curve. The R-squared value and equation of the trendline was present on the graph.
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Figure 17. qRT-PCR Curves from SPTBN1 Knockdown.
RNA samples isolated from CHME3 cells that were transfected with SPTBN1 siRNAs based on
two protocols. The qRT-PCR was performed to quantify the RNA levels using SPTBN1 and
GAPDH primers. Relative fluorescence unit (RFU) indicates the level of fluorescence.
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Figure 18. SPTBN1 Knockdown Calculations.
The Pfaffl method was used to determine the expression of SPTBN1 normalized to the
housekeeping gene GAPDH. The Pfaffl efficiency (Ep) was taken to the power of the change in
cycle number (CT) that the RNA product was amplified by qRT-PCR.

58

Figure 19. Comparing the Effectiveness of Two siRNA Knockdown Protocols.
The expression levels of SPTBN1 were quantified by qRT-PCR and calculated using the Pfaffl
method. The knockdown of two protocols was compared with the expression shown as a
decimal.

Figure 20. SPTBN1 Expression After siRNA Knockdown.
Two siRNA knockdown procedures were used to decrease SPTBN1 expression. The blue bars
were the new knockdown protocol runs and the green were the old knockdown protocol runs.
The expression of SPTBN1 was calculated as previously described in the Pfaffl method.
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Figure 21. HIV Infectivity after SPTBN1 Knockdown 10-13-22.
With the new siRNA knockdown protocol on 10-13-22, CHME3 cells were then infected with
HIV with a GFP reporter. The percent of cells infected was determined by flow cytometry and
shown as percent GFP+ cells. Infection was normalized to the non-targeting knockdown samples
at 1, shown with a red line. The no virus controls for SPTBN1 and NT were 0.12% and 0.08%
respectively.

Figure 22. HIV Infectivity with SPTBN1 Knockdown 10-26-22 Experiment.
A second run of the siRNA knockdown new protocol was done with GFP reporter HIV infection.
The infectivity indicated as GFP+ cells, was compared to the non-targeting siRNA transfection at
1 shown by a red line. The no virus controls for SPTBN1 and NT were 0.12% and 0.07%
respectively.
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Figure 23. HIV Infectivity after SPTBN1 siRNA Knockdown 3-8-22.
The old siRNA knockdown protocol was used, and the cells were infected with HIV-GFP.
Infectivity was determined by flow cytometry as GFP+ cells and normalized to the non-targeting
siRNA transfection at 1 shown with a red line. The no virus controls for SPTBN1 and NT were
0.08% and 0.06% respectively.

Figure 24. HIV Infectivity with SPTBN1 siRNA Knockdown 3-27-22.
Cells were infected with HIV-GFP after SPTBN1 knockdown using the old protocol. Infectivity
was represented as GFP+ cells determined by flow cytometry. The percent infection was
normalized to the non-targeting knockdown transfection at 1 shown by a red line. The no virus
controls for SPTBN1 and NT were 0.05% and 0.08% respectively.
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Figure 25. HIV Fusion Assay with Various Ammonium Chloride Concentrations.
A fusion assay was done with adding in different concentrations of ammonium chloride. The
infectivity was determined by flow cytometry and was shown as percent GFP+ cells.

Figure 26. Fusion Kinetics Overtime.
A fusion assay was performed with 10 mM ammonium chloride added into cells infected with
HIV. The add in was done over time and infectivity determined by flow cytometry shown as
percent GFP+ cells.
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Figure 27. Expression of SPTBN1 after Knockdown for Fusion Assays.
For each fusion assay, the knockdown percentage of SPTBN1 was determined. The Pfaffl
method was used to find the expression change from qPCR results compared to the non-targeting
transfected samples with GAPDH as the housekeeping control.

Figure 28. HIV Fusion Kinetics After siRNA Knockdown 7-7-22.
CHME3 cells were transfected with SPTBN1, NT, or no siRNA and a fusion assay was
performed by adding NH4Cl at various time points after infection (n=2). Percent GFP+ cells
were determined by flow cytometry to indicate the HIV infection rate for each sample. The
infectivity of SPTBN1 knockdown cells is the blue diamonds and the NT is red squares.
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Figure 29. HIV Fusion Kinetics following SPTBN1 Knockdown 9-2-22.
Cells were transfected with SPTBN1 or NT siRNAs, infected with HIV-GFP, and a fusion
inhibitor was added overtime to determine the fusion kinetics (n=3). Error bars indicate the
standard deviation from the triplicate reactions. Flow cytometry was done to determine the
number of cells that expressed GFP that indicates infection. The fusion of SPTBN1 is shown by
the blue diamonds and NT is indicated by red squares.
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Figure 30. Fusion Assay After SPTBN1 Knockdown 9-16-22.
Microglial cells were transfected with SPTBN1, NT, or no siRNA before HIV infection.
Following infection, the fusion inhibitor NH4Cl was added in overtime to determine the fusion
kinetics (n=3). Error bars indicate the standard deviation from the triplicate reactions. Infection
percentage was determined by flow cytometry. SPTBN1 (blue diamonds) and NT (red square)
siRNA transfected samples were compared on the percent of HIV infection (A). The values were
normalized to the highest percent infection of that sample (B).
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DISCUSSION

Bioinformatics was performed to ensure the targets of qPCR primers and siRNAs were in
ideal locations and unique to the gene in question. The qPCR primers should be in different
exons with an intron in the middle to ensure the primers are amplifying mature RNA or cDNA.
The product size should not be too small that the polymerase cannot amplify the sequence and a
product of 200 basepairs or less is ideal for qPCR to have the best primer efficiency (86). The
siRNA locations should be in exons spanning the gene to maximize the knockdown. Both qPCR
primers and siRNAs are only present in and affect the SPTBN1 or GAPDH genes. The qPCR
forward and reverse primers for SPTBN1 and GAPDH are in exons with an intron in the middle
(Fig. 9 and 10). The primers amplify a sequence between 100 and 200 basepairs long (Fig. 14
and 15). The siRNAs used were a mixture of 4 sequences that target different locations in the
genes. Both SPTBN1 and GAPDH siRNAs targeted exons or spanned exons throughout the
genes (Fig. 9 and 10). The qPCR primers and siRNAs used in this research meet all of the ideal
characteristics based on the bioinformatics.
There are many qPCR protocols available that can be used depending on what samples
are being tested. The optimization of the qRT-PCR protocol was performed as it is used to
determine the knockdown expression level of SPTBN1. Two protocols were compared to see
which one would have earlier amplification (a smaller Cq) and decreased background (larger Cq
in the negative control). The new qRT-PCR protocol had the reverse transcriptase step included
which is an advantage, making the protocol easier to use and decreasing the probability for
contamination. With the same DNA samples and primers, the iTaq One-Step Kit had earlier
amplification of the targets (GAPDH and SPTBN1) along with less background (Table 2).
Earlier sample dection and less background is likely due to the polymerase. The taq polymerase
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is a hot-start polymerase that requires high temperatures to activate the polymerase (87). This
heat activation allows for reduced off target amplification and decreased primer dimers that
cause greater background. The BioRad information for SsoFast also shows it having a lower
specificity that could cause off target amplifcation resulting in slower detection and increased
background (88). With the qRT-PCR protocol changed, the primer efficiency was recalculated
with the iTaq supermix.
The SsoFast primer efficiency for SPTBN1 and GAPDH primers was determined by
Marc Havlicek with SPTBN1 being 1.05 and GAPDH being 0.79 (75). Starting with the
SPTBN1 primer set and using the iTaq one-step kit, the initial results had a much lower
efficiency of 0.55. Low efficiency is not desired because it would indicate that the supermix and
primers are not efficiently amplifying the products and should not be used together. Because the
primer efficiency was about half of the efficiency that was found with the SsoFast supermix,
each component of the qPCR sample was tested and analyzed to try to increase the efficiency.
The primers were rediluted and used at a higher concentration to ensure there was enough of the
primers to amplify the products. This did not increase the efficiency so it was determined that
was not the cause of the lower efficiency (Fig. 13). The plasmid DNA used intitally was what
Marc Havlicek used and could have degraded in storage so it was grown and reisolated to
determine if that was the cause of the lower efficiency.
The plasmid DNA used contained either the GAPDH or SPTBN1 genes. After the
plasmid DNA was isolated again, confirmation of the genes presence was done (Fig. 14 and 15).
Both genes were present in the respective samples. The primer efficiency of SPTBN1 was
continued with the new plasmid DNA for the dilution series. The SPTBN1 primer efficiency was
determined to be 0.79 which is closer to the SsoFast primer efficiency. The GAPDH primer
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efficiency was determined as well with the new plasmid DNA and is 0.62. Both primer
efficiencies with the iTaq supermix were lower than the SsoFast primer efficiency but that was
expected based on the BioRad website. It shows that SsoFast supermixes have a higher
efficiency than iTaq supermixes (89). This higher efficiency could be due to the additives present
in the SsoFast supermix that allow for the polymerase to amplify the target efficiently. Because
the supermixes are propriertorized, the exact composistion of the mix is not public knowledge.
As experiments continue, it is important to try to optimize the qPCR protocol as new potentially
better products become available. The supermixes may have contain polymerases that amplify
hard targets better, it could contain different additives that increase efficiency, or other various
changes could be more ideal for the samples being tested. With a change in the qPCR supermix,
primer efficiency should be recalculated because the contents of the supermix will affect how
well the primers amplify the product (Table 4 and 5). In future, it could help to quantify the
plasmid DNA using a nanodrop and make a serial dilution based on the concentration of DNA.
This would also verify that the dilution series is accurate, with each dilution being 1/10th of the
previous. This would prevent unnecessary troubleshooting from an experiment with low Rsquared value on the standard curve.
Another protocol that was optimized was the siRNA knockdown protocol to try to
achieve a higher knockdown of SPTBN1. Two protocols were compared, the difference being
the concentration of siRNA, incubation times, the media used on the cells during transfection,
and if a media change was done following transfection (Fig. 31). The highest knockdown of
SPTBN1 previously achieved by Marc Havlicek was 38.7% (75). The Dai Lab achieved about
90% knockdown of SPTBN1 (56). Along with the knockdown, the cells in culture were observed
throughout the process to see if there was a drastic difference in the cells appearance. The initial
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knockdown comparison resulted in the new knockdown procedure decreasing SPTBN1
expression much more than the old knockdown protocol, similar to what was seen in the Dai Lab
(Fig. 19). The cells used with the old transfection procedure appeared more stressed in culture.
The new protocol used less siRNA which could indicate that the old protocol was using too
much siRNA that overwhelmed the cells.
Using the new siRNA transfection protocol, the SPTBN1 knockdown cells were infected
with virus (Fig. 21 and 22). Previous research indicates that SPTBN1 knockdown decreases HIV
infection with Marc Havlicek seeing 38.7% decrease in SPTBN1 expression caused a 37.5%
decrease of infection. The Dai study showed that when SPTBN1 expression is decreased about
90% it causes over a 90% decrease of HIV infection in macrophages. The decrease of SPTBN1
expression did not initially decrease HIV infection in this research (Fig. 21 and 22; (56, 68, 74)).
After SPTBN1 knockdown using the new siRNA transfection protocol, HIV infection stayed the
same or increased compared to NT controls (Fig. 21 and 22). This was an unexpected result and
its possible that the protocol used was not compatible with these cells.
The old protocol was returned to, to replicate the results previously achieved. There was
one slight change to the transfection protocol that Marc Havlicek used. The final step is to add
DMEM without penicillin-streptomycin (PS) to the minimal media already in the well, but in this
research the media was changed completely to DMEM without PS (Fig. 31). The knockdown
achieved after returning to the old transfection protocol was equivalent to the new protocol
knockdown. It is likely that the slight change in the transfection protocol is the reason greater
knockdown is achieved with the old protocol. It is easier on the cells when removing the media
that contains the siRNAs and transfection reagent. Many siRNA transfection procedures have a
media change to remove the transfection media (56, 90). The OPTIMEM media used in the
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transfection protocols is a reduced serum media that starves the cells as they are being
transfected. When cells are starved of nutrients, they are more willing to take in things in their
environment such as siRNAs. The media change in the altered old transfection protocol brings
back the nutrients the cells need and removes the harsh transfection reagent.
Going back to the old siRNA knockdown protocol generated the expected results of
SPTBN1 knockdown decreasing HIV infection at lower virus concentrations (Fig. 23 and 24). In
one experiment with the old transfection protocol, at higher virus concentrations, there was an
increase in infection (Fig. 24). It is possible that there is a threshold of virus that the CHME3
knockdown cells can handle and with high SPTBN1 knockdown and high virus concentration,
the cells become overwhelmed and more susceptible to HIV infection. The Dai study did show a
high knockdown level having equally as high decrease of infection within macrophages (56).
The cells used in this research are microglial cells that are a specialized macrophage in the
central nervous system that could have a different reaction to SPTBN1 knockdown and HIV
infection (91). Microglial cells have a drastically different gene expression profile than
macrophages in the brain and would cause the difference during HIV infection (91). SPTBN1 is
required for the cells and stabilizes the cytoskeleton. The cytoskeleton is altered significantly in
macrophages with actin knockdown, shown by the Dai Lab, which causes stress on the cells (56).
Adding a high concentration of HIV to the already stressed cells could overwhelm them and
result in an increased rated of HIV infection.
To investigate this relationship further, it would be useful to vary the amount of SPTBN1
knockdown and see the change in HIV infection. Changing the concentration of siRNA in
transfection would be a good start to lessen the amount of knockdown. With a drastically smaller
concentration of siRNA, there wouldn’t be enough available to completely knockdown SPTBN1
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in every cell, but it may provide slightly decreased expression in all the cells. A dilution series of
siRNA concentrations could be tested to see if the knockdown amount can be strategically
achieved. If the siRNA knockdown can be less severe, the infectivity would then be tested to see
if there is a correlation in the knockdown percentage to the decrease of HIV infection. From
Marc Havlicek and the Dai study it seems there is the same decrease of HIV infection as
SPTBN1 knockdown. This research did not generate the results the Dai study did where 90%
knockdown caused a 90% decrease of infection (56). In this research when the knockdown of
SPTBN1 was 80-90% the infectivity decreased consistently around 20% (Fig. 23, 24, and 30B).
This again could be due to the microglial cells being overwhelmed with the siRNA knockdown
and not having the same level of effect on infectivity. The Dai study did use a decreased amount
of siRNA at 50 M and had a media change following transfection (56). It is possible the siRNA
concentration is too high in the old transfection protocol and causing more off target problems
when HIV it trying to infect the cells. Further adjustments to the siRNA protocol should be done
to see how that changes HIV-1 infection.
Troubleshooting the siRNA protocol could start with using the RNAiMAX transfection
protocol but using the media the old transfection protocol used (Fig. 31). If the cells have the
OPTIMEM media during transfection and a media change after transfection but everything else
as in the RNAiMAX protocol it could be a starting point to what parts of the protocol are causing
the increased knockdown. I would start by changing one step in the protocol at a time and
continue from there, looking at the siRNA concentration, media present on the cells, and
incubation times to further optimize the protocol.
The confirmation of SPTBN1 playing a role in HIV infection led to the question of what
step in the infection process is it involved. Marc Havlicek found that SPTBN1 knockdown
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altered uncoating kinetics (75). Because fusion is prior to uncoating, it is important to verify that
fusion delay was not the reason uncoating was delayed. Therefore, Aim 2 of this thesis research
determined whether HIV fusion kinetics was altered after SPTBN1 knockdown. It was
hypothesized that SPTBN1 knockdown would affect HIV fusion kinetics in microglial cells.
CHME3 cells without SPTBN1 knockdown have similar fusion to many other cell types (Fig.
26; (84, 85)). The fusion kinetics after SPTBN1 knockdown were compared to the NT control to
see if there was a change. The half-life of fusion with SPTBN1 and NT transfected cells was
calculated, and statistical analysis performed by an independent t-test. The SPTBN1 knockdown
did not affect fusion of HIV (Fig. 28-30; Table 6). The half-life of HIV fusion for SPTBN1
knockdown was 16 minutes and 7 seconds, the NT was 19 minutes and 10 seconds (Table 6).
These half-life times are not statistically different from each other (p=0.648). SPTBN1
knockdown decreases overall infection and is observed in the fusion experiments with lower
percentages of infected cells compared to the NT (Fig. 28-30). When the experiments are
normalized to the maximum amount of infection, the fusion rate is the same (Fig. 30). This
indicates that the SPTBN1 is not involved in HIV-1 fusion, disagreeing with the hypothesis that
SPTBN1 is involved in fusion.
SPTBN1 is an actin associated molecule, and actin localization occurs when HIV is
infecting a cell during the fusion step specifically (66, 92). SPTBN1 organizes the actin
cytoskeleton, without this present it affects the organization and in turn was thought to affect
HIV infection steps that use actin (56). SPTBN1 is involved in HIV infection, but not the fusion
step. This further supports the previous findings that SPTBN1 knockdown is involved in the
uncoating of HIV. There are many future directions that could be performed to further
investigate the role SPTBN1 has on HIV infection.
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The aspirational Aim 3 of this research was not started due to time constraints and would
be a future direction of research. The goal of the third aim is to visualize cytoskeletal elements of
the cells and HIV via fluorescence microscopy to determine possible interactions and
mechanisms of infection. The actin cytoskeleton will be visualized using phalloidin and SPTBN1
visualized by an antibody. There are many experimentation routes that can be taken with these
methods. First the actin and SPTBN1 should be visualized before and after SPTBN1 knockdown.
Before SPTBN1 knockdown, the actin would be a network throughout the cell with SPTBN1
organizing the filaments (56, 71). The actin cytoskeleton with SPTBN1 knockdown would be
greatly affected, creating localized spotting rather than a fluid network (56). The presence of
SPTBN1 should be decreased almost to nonexistent expression. The SPTBN1 location can also
be visualized in relation to HIV virions using dual labeled virus. The dual labeled virus is
pseudotyped with VSV-g envelope and two fluorescent markers within it; the GFP reporter on
the Vpr viral molecule to signify the viral genome and a dTomato or mCherry label bound to the
viral membrane. Dual labeled virus, like all virus used in this research enters the cell through
endocytosis which is different than the fusion of wildtype HIV. The membrane marker of the
dual labeled virus allows for differentiating virus with and without the membrane or virus that
has entered the cytoplasm or not. This would verify that SPTBN1 is not involved in the fusion
step of HIV, expecting the virions with the membrane intact would not colocalize with SPTBN1,
but SPTBN1 should be colocalized somewhere after fusion. The SPTBN1 protein has been
shown to interact with capsid and matrix viral proteins (56). Understanding at what point and
how significantly these viral proteins interact with SPTBN1 is another step in understanding the
mechanism of HIV infection. This could also be observed after SPTBN1 knockdown to see how
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the route of HIV infection is altered. Because it is not likely that SPTBN1 is involved in fusion,
the uncoating of HIV should be looked at again.
Identifying in what way SPTBN1 interacts with the capsid would further verify that the
uncoating step uses actin and associated molecules to be complete. Marc Havlicek found that
uncoating is delayed with SPTBN1 knockdown. The knockdown Marc achieved was 38.7%,
much lower than what is now being achieved. It is important to go back and rerun the uncoating
assays with higher SPTBN1 knockdown to verify that SPTBN1 is still being affected. This could
also indicate if higher SPTBN1 knockdown decreases uncoating at the same or a different rate.
An additional area to look at would be doing fluorescence microscopy but focusing on the
capsid. Using an antibody for SPTBN1 and the HIV capsid would show if there is an interaction
between the two molecules during infection. SPTBN1 has been shown to interact with the capsid
and matrix proteins through immunoprecipitation by the Dai Lab. Visualizing this interaction
during infection is needed to verify SPTBN1 is directly involved in uncoating. The matrix
protein is involved in early replication steps following virus entry including being necessary for
effective uncoating and reverse transcription (93, 94). It would be expected that SPTBN1
antibody would colocalize with the capsid antibody after the capsid is released into the
cytoplasm and before entry into the nucleus.
This leads to the question of what other early infection processes involve SPTBN1. The
Dai Lab showed SPTBN1 interaction with the capsid and matrix proteins, but these two proteins
are involved in more than uncoating (56, 94). Other early replication steps may also involve
SPTBN1, such as trafficking, reverse transcription, and entry into the nucleus. The early steps of
HIV have the capsid and matrix proteins associated and it is necessary to determine whether
SPTBN1 only associates with the viral complex during certain steps or at multiple steps.
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Trafficking towards the nucleus could be initially investigated during the microscopy
experiments to see if SPTBN1 is associated with the viral core for a long time and distance. If it
is shown that SPTBN1 is associated with the HIV core the majority of the time in the cytoplasm,
it likely means it plays a role in reverse transcription as well. Uncoating and reverse transcription
have a lot of interplay and are happening at the same time within the cell (31, 34, 35). The
amount of reverse transcription occurring before and after SPTBN1 knockdown can be tested
similarly to that of fusion, with a reverse transcription inhibitor being added over a time course.
This would indicate if and at what point reverse transcription is affected by SPTBN1
knockdown. The possible involvement of SPTBN1 in viral entry into the nucleus could be
observed using microscopy as well. DAPI staining the nucleus and observing colocalization of
SPTBN1 and the viral core would indicate SPTBN1 is present as HIV is entering the nucleus.
The actin cytoskeleton is involved in entry into the nucleus, so it would be expected that the
scaffolding protein of actin, SPTBN1, would also be present during the HIV core entering the
nucleus (65, 66, 95).
The goal of this thesis research was to determine the role of SPTBN1 in HIV-1 infection.
It verified previous research that SPTBN1 knockdown decreased HIV-1 infection (56, 68, 74).
SPTBN1 knockdown has an effect on HIV-1 uncoating, observed in Marc Havlicek’s thesis
research, and this research shows that it does not have an effect on HIV-1 fusion (75). Therefore,
this supports the conclusion that SPTBN1 is involved with the uncoating step of HIV infection.
Understanding the HIV-1 replication cycle is imperative to finding a possible mechanism for
treatments and a cure for those living with HIV.
HIV has been shown to interact with many microtubule associated proteins, but
interaction with an actin associated protein gives more insight to how HIV infects microglia
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cells. Microglia cells are long lasting cells and the innate immune systems defense within the
central nervous system (17). These cells protect the CNS from infection that can lead to severe
neurological defects. HIV infection of microglial cells are a large portion of the HIV reservoir
where the viral DNA lays dormant within cells. The HIV reservoir is the biggest battle when
trying to treat and cure HIV infection because the cells are not actively producing virus but after
each cell division the progeny also contain the viral DNA (17). Preventing initial HIV infection
in all cells, microglial cells especially is a major goal of HIV research. If a block to HIV
infecting a cell is determined, once someone is exposed, treatment can be given, and chronic
HIV infection avoided. Much of HIV research is trying to better understand the infection process
and what cellular factors are involved. Once the mechanisms of HIV infection are uncovered,
treatments to block those processes can be formulated to decrease and eventually irradicate HIV.
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Figure 31. siRNA Transfection Protocol Comparison.
Two siRNA transfection protocols were compared to increase knockdown of SPTBN1. The
general protocol stated in the diagram with arrows showing where the two protocols differ. The
old transfection protocol was used by previous graduate students and the RNAiMAX transfection
protocol comes with the reagents (80).
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